Cover Page for Protocol  
 
Sponsor name:  Novo Nordisk A/S 
NCT number [STUDY_ID_REMOVED] 
Sponsor trial ID: NN1436-4383 
Official title of study: An investigational trial comparing the efficacy and safety of 
once weekly  NNC0148-0287 C (insulin 287) versus once daily 
insulin glargine, both in  combination with metformin, with or 
without DPP -4 inhibitors, in insulin na√Øve subjects with type 2 
diabetes mellitus 
Document date: 29 May 2020 
 
/LQN
/LQN/LQNList of contents
Protocol ....................................................... ............................................................... .........................
Log of protocol................................................ ............................................................... .....................
Key staff in TMF ............................................... ............................................................... ..................&21),'(17,$/'DWH Novo Nordisk
9HUVLRQ
6WDWXV11&
7ULDO,'11&OLQLFDO7ULDO5HSRUW
$SSHQGL[0D\

)LQDO
16.1.1 Protocol and protocol amendments
 CONFIDENTIAL
 
 
 
 
 
Redacted protocol 
Includes redaction of personal identifiable information only. 
 
 
 
. 
 
 
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 1 of 94
Protocol
Protocol title: An investigational trial comparing the efficacy and safety of once weekly 
NNC0148-0287 C (insulin 287) versus once daily insulin glargine, both in 
combination with metformin, with or without DPP-4 inhibitors, in insulin na√Øve 
subjects with type 2 diabetes mellitus
Substance: NNC0148-0287 C (insulin 287)
Universal Trial Number: U1111-1208-4124 
EUdraCT Number:2018-000322-63 
Trial phase: 2
In the following, Novo Nordisk A/S and its affiliates will be stated as ‚ÄúNovo Nordisk‚Äù.
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
 CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 2 of 94
Table of Contents   
Page
Table of Contents.............................................................................................................. ..........................2
1 Synopsis...................................................................................................................... ..........................5
2 Flowchart ..................................................................................................................... ........................8
3 Introduction .................................................................................................................. .....................12
3.1 Trial rationale ..........................................................................................................................12
3.2 Background .............................................................................................................................12
3.3 Benefit-risk assessment ..................................................................................................... ......14
3.3.1 Benefits .................................................................................................................1 4
3.3.2 Risks ..................................................................................................................... .14
3.3.3 Conclu sion on the benefit risk profile .....................................................................16
4 Objectives and endpoints ...................................................................................................................16
4.1 Primary, secondary and exploratory objectives ........................................................................16
4.1.1 Primary objective ...................................................................................................16
4.1.2 Secondary objective ...............................................................................................16
4.1.3 Expl oratory objectives ...........................................................................................16
4.2 Primary estimand ....................................................................................................................17
4.2.1 Sec ondary estimand ...............................................................................................17
4.3 Primary, secondary and exploratory endpoints .........................................................................17
4.3.1 Prima ry endpoint ...................................................................................................17
4.3.2 Sec ondary endpoints ..............................................................................................17
4.3.2.1 Confirmatory endpoints ....................................................................17
4.3.2.2 Supportive sec ondary endpoints .......................................................17
4.3.3 Exploratory en dpoints............................................................................................19
5 Trial design .................................................................................................................. ......................19
5.1 Overall design.............................................................................................................. ...........19
5.2 Subject and trial completion ....................................................................................................20
5.3 End of trial definition ..............................................................................................................20
5.4 Treatment emergent period ......................................................................................................21
5.5 Scientific rationale for trial design ...........................................................................................21
5.6 Justification for dose ...............................................................................................................22
6 Trial population .............................................................................................................. ...................23
6.1 Inclusion criteria .....................................................................................................................23
6.2 Exclusion criteria ....................................................................................................................23
6.3 Lifestyle restrictions ................................................................................................................24
6.4 Fasting requirements ...............................................................................................................25
6.5 Screen failures ............................................................................................................. ...........25
6.6 Randomisation criteria ............................................................................................................25
7 Treatments .................................................................................................................... .....................25
7.1 Treatments administered .........................................................................................................25
7.1.1 Non-i nvestigational medical products .....................................................................26
7.1.2 Aux iliary supplies ..................................................................................................27
7.1.3 Medical devices .....................................................................................................27
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 3 of 94
7.2 Dose modification ...................................................................................................................27
7.3 Method of treatment assignment ..............................................................................................28
7.4 Blinding.................................................................................................................... ..............28
7.5 Preparation/Handling/Storage/Accountability ..........................................................................28
7.6 Treatment compliance .............................................................................................................29
7.7 Concomitant medication ..........................................................................................................30
7.7.1 An cillary treatment ................................................................................................30
7.8 Treatment after the end of the trial ...........................................................................................30
8 Discontinuation/Withdrawal criteria ................................................................................................31
8.1 Discontinuation of trial treatment ............................................................................................31
8.2 Withdrawal from the trial ........................................................................................................32
8.2.1 Rep lacement of subjects .........................................................................................33
8.3 Lost to follow-up........................................................................................................... ..........33
9 Trial assessments and procedures .............................................................................................. .......33
9.1 Efficacy assessments ...............................................................................................................34
9.1.1 Self-meas ured plasma glucose ................................................................................34
9.1.2 Insulin dos e ...........................................................................................................35
9.1.3 Flash Glucose M onitoring......................................................................................35
9.1.3.1 FGM Reader setting .........................................................................36
9.1.3.2 Fitting and remova l of the FGM sensor .............................................36
9.1.3.3 Duration of  FGM periods .................................................................37
9.1.3.4 Wearing of th e FGM sensor ..............................................................37
9.1.3.5 Transfer of FGM data .......................................................................37
9.1.4 Clin ical efficacy laboratory assessments .................................................................37
9.2 Adverse events.............................................................................................................. ..........37
9.2.1 Time period and frequency for collecting AE and SAE information ........................37
9.2.1.1 Event for adjudication ......................................................................39
9.2.2 Met hod of detecting AEs and SAEs .......................................................................40
9.2.3 Follow-up on AEs and SAEs..................................................................................40
9.2.4 Regul atory reporting requirements for SAEs ..........................................................40
9.2.5 Cardi ovascular and death events .............................................................................41
9.2.6 Disease-related events and/or disease-related outcomes not qualifying for 
standard AE collection ...........................................................................................41
9.2.7 Pregna ncies and associated adverse events .............................................................41
9.2.8 Medi cal device incidents (including malfunctions) .................................................42
9.2.9 Tec hnical complaints .............................................................................................42
9.3 Treatment of overdose .............................................................................................................43
9.4 Safety assessments .......................................................................................................... ........43
9.4.1 Phys ical examinations ............................................................................................44
9.4.2 V ital signs ..............................................................................................................44
9.4.3 Electrocardiograms ................................................................................................45
9.4.4 Eye examinat ion ....................................................................................................45
9.4.5 Clin ical safety laboratory assessments ....................................................................45
9.4.6 Imm unogenicity assessments .................................................................................46
9.4.6.1 Assessments in case of suspicion of hypersensitivity reaction to 
trial product ......................................................................................46
9.5 Pharmacokinetics ....................................................................................................................47
9.6 Pharmacodynamics .................................................................................................................47
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 4 of 94
9.7 Genetics ............................................................................................................................... ...47
9.8 Biomarkers .................................................................................................................. ...........47
10 Statistical considerations ...................................................................................................................47
10.1 Sample size determination .......................................................................................................47
10.2 Definition of analysis sets ........................................................................................................48
10.3 Statistical analyses ..................................................................................................................49
10.3.1 Prima ry endpoint ...................................................................................................50
10.3.2 Sec ondary endpoints ..............................................................................................52
10.3.3 Confirmatory secondary endpoints .........................................................................52
10.3.3.1 Supportive secondary endpoints .......................................................52
Efficacy endpoints .................................................................................................52
Safety endpoints ....................................................................................................53
10.3.3.2 Exploratory en dpoints ......................................................................56
10.4 Pharmacokinetic and/or pharmacodynamic modelling .............................................................60
11 References ............................................................................................................................... ...........61
12 Appendices ............................................................................................................................... ..........64
Abbreviations and Trademarks.......................................................................................64 Appendix 1
Clinical laboratory tests ...................................................................................................66 Appendix 2
Trial governance considerations......................................................................................68 Appendix 3
Adverse events: definitions and procedures for recording, evaluation, follow-up, Appendix 4
and reporting.................................................................................................................. ..78
Contraceptive guidance and collection of pregnancy information .................................83 Appendix 5
Technical complaints: Definition and procedures for recording, evaluation, follow- Appendix 6
up and reporting............................................................................................................... 86
Retention of human biosamples.......................................................................................87 Appendix 7
Hypoglycaemic episodes...................................................................................................88 Appendix 8
Titration guideline ............................................................................................................90 Appendix 9
Country-specific requirements ........................................................................................94 Appendix 10
Attachment I Global list of key staff and relevant departments and suppliers
Attachment II Country list of key staff and relevant departments
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 5 of 94
1 Synopsis
Rationale:
NNC0148-0287 formulation C (referred to as insulin 287) may provide an efficacious, safe and 
convenient once weekly alternative to once daily  basal insulin, which could improve treatment 
adherence and quality of life for sub jects with type 2 diabetes mellitus. 
The purpose of the present randomised, treat-to-target tr ial is to investigate efficacy and safety of 
once-weekly insulin 287 versus once-daily insulin  glargine, both in combination with metformin 
with or without dipeptidyl peptidase-4 inhibitors, for 26 weeks in subjects with type 2 diabetes insufficiently controlled on metformin ¬±dipeptidy l peptidase-4 inhibitors. Glycated haemoglobin
(HbA
1c) will be included as the primary endpoint since it is considered the most widely accepted 
measure of overall, long-term glucose control by the European Medicines Agency (EMA) and Food 
and Drug Administration (FDA) guidance documents.
Objectives and endpoints
Primary objective
To investigate the effect on glycaemic control after 26 weeks treatment of once weekly insulin 287 
versus once daily insulin glargine both in combination with metformin with or without dipeptidyl peptidase-4 inhibitors in insulin-na√Øve type 2 diabetes mellitus subjects inadequately treated with 
metformin with or without dipeptidyl peptidase-4 inhibitors.
Secondary objective
To investigate the safety and tolerability duri ng 26 weeks of treatment with once weekly insulin 287 
versus once daily insulin glargine both in combination with metformin with or without dipeptidyl 
peptidase-4 inhibitors in insulin-na√Øve subjects with type 2 diabetes mellitus inadequately treated 
with metformin with or without dipeptidyl peptidase-4 inhibitors.
Primary endpoint
Change from baseline (visit 2, week 0) to week 26 (visit 28) in HbA
1c(%-point and [mmol/mol])
Estimand
The primary estimand is defined as the treatment difference in change of HbA 1cfrom baseline to 
week 26 between once weekly insulin 287 and once daily insulin glargine for all randomised subjects, if all subjects had adhered to treatment and did not r eceive ancillary treatment.
This is a ‚Äòhypothetical‚Äô estimand aiming to reflect the treatment effect for subjects that are actually 
able to take the drug during the intended treatment period.
Overall design:
This is a 26-week, randomised, double-blind, double-dummy, active-controlled, parallel-group, 
stratified, multicentre, multinational trial with  2 arms comparing the efficacy and safety of 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 6 of 94
treatment with insulin 287 once weekly versus insu lin glargine once daily in insulin-naive subjects 
with type 2 diabetes mellitus inadequately cont rolled on metformin with or without dipeptidyl 
peptidase-4 inhibitors.
Subjects will be randomised in a 1:1 manner to receive once weekly insulin 287 and once daily 
placebo or once weekly placebo and once daily insulin glargine. The randomisation of subjects will 
be stratified based on use of dipeptidyl peptidase-4 inhibitors.
Key inclusion criteria:
!Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent.
!Diagnosed with type 2 diabetes mellitus ‚â• 180 days prior to the day of screening.
!HbA 1cof 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central laboratory.
!Stable daily dose(s) for 90 days prior to the day of screening of any of the following anti-
diabetic drug(s) or combination regime(s):
a) Any metformin formulations ‚â• 1500 mg or maximum tolerated or effective dose (as 
documented in subject's medical record) 
b) Any metformin formulations ‚â• 1500 mg or maximum tolerated or effective dose (as 
documented in subject medical record) with DPP4i ( ‚â• half of the maximum approved 
dose according to local label or maximum tolerated or effective dose (as documented in subject's medical records)
!Insulin na√Øve. However, short term insulin treatment for a maximum of 14 days prior to the 
day of screening is allowed, as is prior insulin treatment for gestational diabetes.
!Body mass index (BMI) ‚â§ 40.0 kg/m
2
Key exclusion criteria:
!Any episodes of diabetic ketoacidosis within th e past 90 days prior to the day of screening 
and between screening and randomisation.
!Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient 
ischaemic attack within 180 days prior to the day of screening and between screening and 
randomisation.
!Presently classified as being in New York Heart Association (NYHA) Class IV.
!Treatment with any medication for the indication of diabetes or obesity other than stated in 
the inclusion criteria within the past 90 days prior to the day of screening. However, short 
term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as 
is prior insulin treatment for gestational diabetes.
!Anticipated initiation or change in concomitant medications (for more than 14 consecutive 
days) known to affect weight or glucose me tabolism (e.g. treatment with orlistat, thyroid 
hormones,  or corticosteroids).
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 7 of 94
!Uncontrolled and potentially unstable diabetic reti nopathy or maculopathy. Verified by a 
pharmacologically pupil-dilated fundus examin ation performed by an ophthalmologist or 
another suitably qualified health care provider within the past 90 days prior to screening or 
in the period between screening and randomisation.
Randomisation criterion:
!Subject able and willing to adhere to the protocol including self-administered daily 
injections using vial and syringe based on the Investigator‚Äôs judgment.
Number of subjects:
!Number of subjects planned to be randomised: 250 subjects
!Estimated number of subjects to complete the trial (on trial product): 215.
Treatment groups and duration:
The total trial duration for the individual subject will be approximately 33 weeks. The trial includes 
a 2 week screening period, followed by a 26-week randomised treatment period and a 5-week follow-up period. 
Trial products:
Investigational medical products:
!Test product: 
oNNC0148-0287 C 4200 nmol/mL in a 3 mL PDS290 pre-filled pen-injector with for 
subcutaneous injection
!Reference therapies: 
oInsulin glargine 100U/ml, 10 ml v ials for subcu taneous in jection
oNNC0148-0287 C and insulin glargine placebo (double dummy trial)
 CONFIDENTIAL
Protocol      Date: 25 June 2018 Status: Final Novo Nordisk
Trial ID: NN1436-4383      Version: 1.0 Page: 8 of 94
2 Flowchart
Trial PeriodsScreeningRandomisationTreatmentEnd of 
treatment1Follow upDiscontinuation 
phone contacts
(Px)Discontinuation
follow-up
Visit (V)
Phone contact (P)V1 V2 V3 V4 V5 V6 P7 V8 P9 V10 P11 V12 P13 V14 P15
P16
P17V18 P19
P20
P21V22 P23
P24
P25V26 P27 V28 V29
FU1V30
FU2Every
4 
weeksV28A
Time of visit (weeks)2‚â§-2 0 1 2 3 4 5 6 7 8 9 10 11 12 13
14
1516 17
18
1920 21
22
2324 25 26 28 31 26
Visit window (days) ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 +3 +3 ¬±3
SUBJECT RELATED INFORMATION AND ASSESSMENTS
Informed consent X
In/exclusion criteria X X
Randomisation criterion X
Concomitant illness/
medical historyX
Concomitant medication X X X X X X X X XXXXXXXXXXXXXX X3X3X3X3
Demography4X
Diabetes history/Diabetes 
complicationsX
Date of Diagnosis of Diabetes X
Childbearing potential X
Tobacco use5X
Body measurements
Height X
                                               
1If subjects are discontinuing trial product prematurely they will be asked to attend the end of treatment visit (V28) as soon as  possible and the follow up visits (V29 and 
V30) must be scheduled 2 and 5 weeks after discontinuation of trial product. After the follow-up period, the subjects discontin uing trial product prematurely should have 
phone contacts (Px) scheduled every 4 weeks until the discontinuation follow-up visit (28A) performed at week 26.
2Time of visit is relative to randomisation (V2).
3Only antidiabetic medication to be collected 
4Demography consists of date of birth or year of birth and/or age, sex, ethnicity and race (according to local regulation).
5Smoking is defined as smoking at least one cigarette or equivalent daily.
 
Protocol      Date: 25 June 2018 Status: Final Novo Nordisk
Trial ID: NN1436-4383      Version: 1.0 Page: 9 of 94
Trial PeriodsScreeningRandomisationTreatmentEnd of 
treatment1Follow upDiscontinuation 
phone contacts
(Px)Discontinuation
follow-up
Visit (V)
Phone contact (P)V1 V2 V3 V4 V5 V6 P7 V8 P9 V10 P11 V12 P13 V14 P15
P16
P17V18 P19
P20
P21V22 P23
P24
P25V26 P27 V28 V29
FU1V30
FU2Every
4 
weeksV28A
Time of visit (weeks)2‚â§-2 0 1 2 3 4 5 6 7 8 9 10 11 12 13
14
1516 17
18
1920 21
22
2324 25 26 28 31 26
Visit window (days) ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 +3 +3 ¬±3
Body weight6X X X X X
EFFICACY
Glucose metabolism
HbA 1c X X X X X X X X X
Fasting plasma glucose X X X
Fasting C-peptide X X X
Self-measured plasma glucose 
(SMPG)7 XXXXXXXXXXXXXXXXXXXXX
9-point profile8XX X
PK sampling X X X X X X X
OTHER ASSESSMENTS
Flash glucose monitoring, fittingXXX XX
Flash glucose monitoring, 
removal and uploadXXX X X
SAFETY
A d v e r s e e v e n t s X XXXXXXXXXXXXXXXXXXXXXXX X X
Hypoglycaemic episodes X X X X X X X XXXXXXXXXXXXXXXX
Technical complaints X X X X X X X XXXXXXXXXXXXXX
ECG9X X
                                               
6Body weight should be measured fasting except for V1 and V28A.
7Subjects will measure once daily pre-breakfast SMPG.
8The 9-point profile must be performed  in the week prior to visits, on a day where the subject does not anticipate unusual stre nuous exercise
9ECG obtained within 2 weeks prior to V2 and V28 are acceptable if results are available for evaluation at the visits.
 
Protocol      Date: 25 June 2018 Status: Final Novo Nordisk
Trial ID: NN1436-4383      Version: 1.0 Page: 10 of 94
Trial PeriodsScreeningRandomisationTreatmentEnd of 
treatment1Follow upDiscontinuation 
phone contacts
(Px)Discontinuation
follow-up
Visit (V)
Phone contact (P)V1 V2 V3 V4 V5 V6 P7 V8 P9 V10 P11 V12 P13 V14 P15
P16
P17V18 P19
P20
P21V22 P23
P24
P25V26 P27 V28 V29
FU1V30
FU2Every
4 
weeksV28A
Time of visit (weeks)2‚â§-2 0 1 2 3 4 5 6 7 8 9 10 11 12 13
14
1516 17
18
1920 21
22
2324 25 26 28 31 26
Visit window (days) ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 +3 +3 ¬±3
Eye Examination X10X11
Physical Examination X X
Vital signs X X X X
Biochemistry X X X X X X X X
Lipids X X X
Free Fatty Acids X X X
Haematology X X X X
Pregnancy test12XX X
Antibodies X X X X X X
TRIAL MATERIAL
Drug accountability X X X X X X X
Dispensing visit X X X X X X
Dose of trial insulin13XXXXXXXXXXXXXXXXXXX X14X
REMINDERS
Handout ID card X
Attend visit fasting X X X
                                               
10Eye examination obtained within 90 days prior to V2 as part of routine practise may replace the screening assessment if results  are available for evaluation at V2. 
11Eye examinations performed within 2 weeks prior to V28 are acceptable if results are available for evaluation at the visit. For  treatment-discontinued subjects, eye 
examination can be performed up to 2 weeks after V28.
12For females of childbearing potential a serum pregnancy test must be performed at V1 and V30. At V2 and if a menstrual period i s missed, a urine pregnancy test will 
be taken. 
13The first 5 doses of once-weekly insulin 287 or once-w eekly placebo will be taken at the site (V2 to V6).
14The last dose of once weekly insulin/placebo must be taken 25 weeks after randomisation, whereas the last dose of the once daily insu lin/placebo must be taken  26 
weeks after randomisation where the subjects come in for the end of treatment visit (V28). This is due to the longer half life of Insul in 287.
 
Protocol      Date: 25 June 2018 Status: Final Novo Nordisk
Trial ID: NN1436-4383      Version: 1.0 Page: 11 of 94
Trial PeriodsScreeningRandomisationTreatmentEnd of 
treatment1Follow upDiscontinuation 
phone contacts
(Px)Discontinuation
follow-up
Visit (V)
Phone contact (P)V1 V2 V3 V4 V5 V6 P7 V8 P9 V10 P11 V12 P13 V14 P15
P16
P17V18 P19
P20
P21V22 P23
P24
P25V26 P27 V28 V29
FU1V30
FU2Every
4 
weeksV28A
Time of visit (weeks)2‚â§-2 0 1 2 3 4 5 6 7 8 9 10 11 12 13
14
1516 17
18
1920 21
22
2324 25 26 28 31 26
Visit window (days) ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 ¬±1 +3 +3 ¬±3
Hand out direction for use15X
Training in trial product 
handling and titrationX16X17X X X XXXXXXXX
Hand out and instruct in BG 
meter X
IWRS session X X X X X X X X
H a n d  o u t  a n d  i n s t r u c t  i n  d i a r y X X X X X XXXXXXXXX X
Collect and review diary X X X X X X X XXXXXX X X
End treatment X
End of trial X18X
                                               
15Directions for use can be handed out as needed at subsequent visits.
16Subjects must be trained in the use of vial and syringe at V1, by having the subjects inject themselves with saline solution at site. If deemed necessary by the 
investigator, it could be considered to have the subjects inject themselves with saline solution at home between V1 and V2. At V2 the ability to self-administer daily 
injections will have to be assessed prior to randomisation.
17Subjects must be trained in handling of the PDS290 pre-filled pen-injector at V2.
18Not applicable for subjects discontinuing trial product prematurely, these will have ‚Äúend of trial‚Äù at V28A.
 
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 12 of 94
3 Introduction 
3.1 Trial rationale
NNC0148-0287 formulation C (referred to as insulin 287) is a novel long-acting insulin analogue 
which is designed for subcutaneous (s.c.) administration with the aim to develop a once weekly 
injectable basal insulin treatment. Currently the basal insulin products with the longest duration are 
administered once daily.
Research has shown that people with diabetes would prefer fewer injections and increased 
flexibility than provided by the current once-daily tr eatment regimen.1  Development of sustained 
release formulations or compounds with prolonged action has in several treatment areas been 
demonstrated to improve subject compliance and treatment outcomes. Hence, insulin 287 would be 
a convenient basal insulin which could improve treatment adherence and quality of life for subjects with type 2 diabetes mellitus (T2DM). 
The present randomised, treat-to-target trial will investigate efficacy and safety of once-weekly 
insulin 287 (formulation C) versus once-daily insulin glargine (IGlar), both in combination with 
metformin with or without dipeptidyl peptidase-4 inhibitors (DPP4i), for 26 weeks in subjects with type 2 diabetes insufficiently controlled on metformin ¬±DPP4i . HbA
1cwill be included as the 
primary endpoint since it is considered the most  widely accepted measure of overall, long-term 
glucose control by the European Medicines Agency (EMA) and Food and Drug Administration 
(FDA) guidance documents.2, 3
3.2 Background
Diabetes mellitus
Diabetes mellitus is a metabolic disorder char acterised by the presence of hyperglycaemia due to 
defective insulin secretion, insulin action or both . The chronic hyperglycaemia of diabetes mellitus 
is associated with significant long term sequelae, particularly damage, dysfunction and failure of various organs, especially the kidney, ey e, nerves, heart and blood vessels.
Type 2 diabetes is a complex disorder which i nvolves various degrees of decreased beta- cell 
function, peripheral insulin resistance and abnormal hepatic glucose metabolism. Glucose control in type 2 diabetes may deterior ate progressively over time. The American Diabetes Association 
(ADA) recommend a premeal glucose target of 80‚Äì130 mg/dL (4.4‚Äì7.2 mmol/L) to achieve 
glycaemic control.
4On average, after failure of diet and exercise alone, subjects require a new 
intervention with glucose-lowering agents every 3-4 years in order to obtain/retain good glycaemic 
control.2Despite combination therapy and/or insulin treatment, a sizeable proportion of subjects 
remain poorly controlled.2
Improvement in long-term glucose control, as obtained  with intensified insulin therapy, was shown 
in the UK Prospective Diabetes Study (UKPDS)5to reduce the incidence of microvascular 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 13 of 94
complications and delay the progression of existing complications in people with T2DM. For 
subjects with T2DM who are not achieving glycaemic goals with oral antidiabetic drugs (OADs), 
drug intensification, including insulin therapy, should not be delayed.6
Insulin 287
Insulin 287 is a novel long-acting basal insulin analogue with a terminal elimination half-life of 
approximately 196 hours (trial NN1436-4314). The molecu le consists of a peptide backbone and a 
side-chain (coupled by acylation). The peptide backbone is more resistant towards proteolytical degradation compared to human insulin and the side chain gives a strong binding to albumin.Insulin 287 has been formulated as a 4200 nmol/mL solution, equivalent to 700 units/mL, 
anticipating that the insulin 287 molecule is equipotent to once-daily basal insulins. A first human 
dose trial with single doses in healthy subjects and in subjects with type 1 diabetes and two multiple-dose trials in subjects with type 2 di abetes have been completed. The pharmacokinetics 
(PK) properties of subcutaneous insulin 287 (formulation C) following 5 weeks of once weekly 
dosing in subjects with type 2 diabetes were i nvestigated in trial NN1436-4314. This trial showed 
that insulin 287 exposure was well distributed across the dosing interval, with a PK profile suitable for once weekly dosing (the geometric mean terminal t¬Ω of insulin 287 was approximately 196 hours), and a peak around 16 hours followed by a slow decline. 
For the pharmacodynamics (PD) properties of s.c. insulin 287 (formulation C), evaluated by glucose 
clamp, the glucose infusion rate response was evenly distributed across the dosing interval. In addition, insulin 287 was well tolerated in subjects with type 2 diabetes. No safety concerns were identified after multiple once-week ly dosing in the dose range of 12 ‚àí24 nmol/kg. No serious or 
severe adverse events (AEs) were reported. No hypersensitivity reactions were reported.  
For further information on previous trials, please refer to the Investigators Brochure.
7
Insulin glargine
Insulin glargine is a once daily long-acting insulin analogue, indicated for treatment of diabetes 
mellitus in combination with oral antidiabetic agents and as part of a basal-bolus insulin regimen. 
Insulin glargine is a widely used basal insulin world-wide and has therefore been selected as comparator in the current trial. For further details, please refer to the EMA Summary of Product Characteristics for insulin glargine (Lantus
¬Æ)8, U.S. Label Information9and manufactures label.
Metformin
Together with life style interventions metformin is considered a first-line antidiabetic therapy in 
subjects with T2DM.6Metformin is a product from the biguanide compound group. Metformin 
lowers plasma glucose levels without increasing the circulating insulin concentrations through 
lowering of the hepatic glucose output and increased insulin sensitivity. For further details, please 
refer to the EMA Summary of P roducts Cha racteristics for Metformin10or locally approved Product 
Information.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 14 of 94
Dipeptidyl peptidase 4 inhibitors
Dipeptidyl peptidase 4 inhibitors (DPP4i) can be used as second line OADs in combination with Metformin
11. DPP4i prevent the hydrolysis of incretin  hormones, thereby increasing plasma 
concentrations of the active forms of glucagon-lik e peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP). Incretin hormones are released by the intestine throughout the 
day, and levels are increased in response to a meal. The incretins are part of an endogenous system 
involved in the physiologic regulation of glucose homeostasis. By enhancing active incretin levels, 
DPP4i increase insulin r elease and decrease glucagon levels in a glucose-dependent manner. For 
further details, please refer to the EMA Summary of  Products Characteristics for the relevant DPP4i 
or locally approved Product Information.
3.3 Benefit-risk assessment
3.3.1 Benefits
Insulin 287 is currently in development for treatment of diabetes mellitus. Insulin 287 has in first 
human dose (FHD) and multiple dose (MD) trials been shown to have a long and stable PK and PD 
profile supporting a once-weekly treatment. Currently  available long-acting basal insulin products 
need to be administered once daily to provide 24-hour coverage. Research has shown that people with T2DM put value in reducing the number of insulin injections.
12Therefore, the compliance and 
quality of life are e xpected to increase by introducing a once-weekly basal insulin tr eatment.
The trial population w ill consist of insulin na√Øve subjects with type 2 diabetes insufficiently 
controlled on metformin ¬±DPP4i. For all subjects participating in this 26 week trial, the anticipated benefits include improved glycaemic control. Titration algorithms, specifying recommended 
adjustments of basal insulin dose at different plasma glucose levels, are used in order to ensure that 
subjects receive an optimal treatment. Subjects will receive intense medical care by means of close contact to the clinical sites with weekly contacts.
3.3.2 Risks
Identified risks for LAI 287 describe undesirable clinical outcomes for which there is sufficient 
evidence that they are caused by LAI287. Potential risks in this section describe undesirable clinical outcomes for which there is scientific evidence to suspect the possibility of a causal relationship with LAI287, but where there is currently insufficient evidence to conclude that this association is 
causal.
13
Identified risks
!Hypoglycaemia
Hypoglycaemia is a common undesirable effect related to the pharmacological mechanism of 
insulin. To mitigate the risk of hypoglycaemia in this trial, frequent blood glucose (BG) measurements will be made throughout drug exposure, and will prevent worsening of 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 15 of 94
hypoglycaemia by early detection and administr ation of carbohydrates and medical treatment, if 
necessary.
Potential risks
!Injection site reactions
Injection site reactions may occur with all injectable drugs.  No injection site reactions were 
reported in trial NN1436-4314 with formulatio n C of insulin 287. However, in this trial 
investigators and subjects will be asked to pay car eful attention to injection site reactions at the 
place of injection; invest igators should ensure careful monitoring and medical evaluation in case 
of injection site reaction occurrence. For furthe r information on injection site reactions, please 
refer to section 9.4.6.1 .
!Hypersensitivity reactions
Severe systemic hypersensitivity reactions may potentially occur following injection of 
therapeutic proteins. No hypersensitivity reactions were reported in trial NN1436-4314 with 
optimised formulation C. During the treatment period in this trial, subjects will have weekly contacts with the site either at visits to the site or with phone contacts. Subjects and investigators will be instructed for signs and sy mptoms of allergic reactions and be instructed to 
contact the site immediately in case of signs of hypersensitivity. For further information on 
hypersensitivity reactions, please refer to section 9.4.6.1 .
!Antibody formation leading to change in clinical effect
An increase in anti-insulin 287 specific antibodies and anti-human insulin antibodies were 
observed for some subjects in trial NN1436- 4314 trial with optimised  formulation C. No 
hypersensitivity reactions were observed in this trial. Moreover, in trial NN1436-4314 higher 
antibody levels seemed to be associated with a longer terminal half-life and reduced clearance 
for insulin 287. In this trial bl ood samples will be analysed for serum antibodies against insulin 
287 at pre-dose time points and at the follow-up visi t. In case of a systemic hypersensitivity 
reaction, blood sampli ng for assessment of antibodies against insulin 287 will be conducted. For 
more information, please refer to section 9.4.6.1 .
!Increase in hepatic enzymes
Transient increases in hepatic enzymes upon init iation of s.c. insulin are considered as potential 
risks due to the pharmacological mechanism of insulin. An increase in hepatic enzyme was observed in nonclinical studies in rats and dogs. No clinically significant changes in hepatic biomarkers have been observed in humans following the administration of insulin 287. In this 
trial, measurements of hepatic biomarkers will be performed at frequent intervals.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 16 of 94
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of insulin 287 may be found in the investigator‚Äôs brochure and any updates 
hereof.7
3.3.3 Conclusion on the benefit risk profile
Based on the non-clinical and clinical development programme, it has been concluded that insulin 
287 is similar to human insulin with respect to pharmacological action and non-clinical safety. 
Insulin 287 was generally well tolerated within the evaluated dose ranges in the first-in-human, single dose escalation trial conducted in healthy subjects , in subjects with type 1 diabetes and in the 
multiple dose trial in subjects with type 2 diabetes mellitus. No safety concerns have been observed 
with LAI287 formulation C; neither elevation in hepatic enzymes nor clinical consequences 
following antibody formation have been reported. With formulation C, no hypersensitivity reactions 
and injection site r eactions were obse rved. To mitigate the risk of hypoglycaemia in this trial, 
frequent blood glucose measurements will be made throughout drug exposure. Therefore, it can be 
concluded that the risk to the sub jects in this trial is considered low. The risk is acceptable in view 
of the benefits a basal insulin with a longer action profile than currently available would provide to 
subjects with diabetes. The overall benefit-ri sk profile of insulin 287 is improved with the 
optimised formulation C and is anticipated to be favourable.
7
4 Objectives and endpoints
4.1 Primary, secondary and exploratory objectives
4.1.1 Primary objective
To investigate the effect on glycaemic control after 26 weeks treatment of once weekly insulin 287 
versus once daily IGlar both in combination with metformin with or without DPP4i in insulin-na√Øve 
T2DM subjects inadequately treated with  metformin with or without DPP4i.
4.1.2 Secondary objective
To investigate the safety and tolerability during 26 weeks of treatment with once weekly insulin 287
versus once daily IGlar both in combination with metformin with or without DPP4i in insulin-na√Øve 
subjects with T2DM inadequately treated with metformin with or without DPP4i.
4.1.3 Exploratory objectives
!To investigate the pharmacokinetics (PK) of insulin 287 using population PK during 26 weeks 
of treatment in insulin na√Øve subjects with T2DM inadequately treated with metformin with or 
without DPP4i
!To investigate the effect on glycaemic control (using FreeStyle Libre Pro) of insulin 
287 and IGlar during 26 weeks of treatment in insulin na√Øve subjects with T2DM inadequately 
treated with metformin with or without DPP4i
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 17 of 94
4.2 Primary estimand 
The primary estimand is defined as the treatment difference in change of HbA 1cfrom baseline to 
week 26 between once weekly insulin 287 and once daily IGlar for all randomised subjects, if all subjects had adhered to treatment and did not receive ancillary treatment.
This is a ‚Äòhypothetical‚Äô estimand aiming to reflect the treatment effect for subjects that are actually 
able to take the drug during the intended treatment period.
4.2.1 Secondary estimand
The secondary estimand is defined as the treatment difference in change of HbA
1cfrom bas eline to 
week 26 between once weekly insulin 287 and once daily IGlar for all randomised subjects, 
regardless of the treatment actually received. 
This estimand aims to reflect the treatment effect for all subjects regardless of treatment adherence, 
i.e., a ‚Äòtreatment policy‚Äô estimand.
4.3 Primary, secondary and exploratory endpoints
4.3.1 Primary endpoint
Endpoint title Time Frame Unit
Change in HbA 1c From baseline (V2) to week 
26 (V28)%-point and 
[mmol/mol]
4.3.2 Secondary endpoints
4.3.2.1 Confirmatory endpoints 
Not applicable for this trial.
4.3.2.2 Supportive secondary endpoints
Supportive secondary efficacy endpoints
Endpoint title Time Frame Unit
Change in fasting plasma 
glucose From baseline (V2) to week 
26 (V28)[mmol/l]
9-point profile (individual 
SMPG values)Week 26 (V28) [mmol/l]
Change in mean of the 9-point 
profile, defined as the area From baseline (V2) to week 
26 (V28)[mmol/l]
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 18 of 94
under the profile
Fluctuations of the 9-point 
profile (defined as the 
integrated absolute distance 
from the mean profile value 
divided by measurement time)Week 26 (V28) [mmol/l]
Change in fasting C-peptide From baseline (V2) to week 
26 (V28)[mmol/l]
Change in body weight From baseline  (V2) to week 
26 (V28)Kilogram 
Weekly dose of insulin 287 
and weekly dose of  IGlar   Week 24-26 (V26-V28) U
Supportive secondary safety endpoints
Endpoint title Time Frame Unit
Number of treatment emergent 
adverse events (TEAEs) From baseline (V2) to week 
31 (V30)Number of events
Number of hypoglycaemic 
alert episodes (level 1) ( ‚â•3.0 
and <3.9 mmol/L ( ‚â•54 and <70 
mg/dL), confirmed by BG 
meter) From baseline (V2) to week 
26 (V28)Number of events
Number of clinically 
significant hypoglycaemic 
episodes (level 2) (<3.0 
mmol/L (54 mg/dL), confirmed 
by BG meter) or severe 
hypoglycaemic episodes (level 
3)From baseline (V2) to week 
26 (V28)Number of events
Number of severe 
hypoglycaemic episodes (level 
3)From baseline (V2) to week 
26 (V28)Number of events
Change in anti-insulin 287 
antibodies level From baseline (V2) to week 
31 (V30)%B/T* 
Change in anti-insulin 287 
antibody titresFrom baseline (V2) to week 
31 (V30)No unit
Change in cross-reactive anti-
human insulin antibody status From baseline (V2) to week 
31 (V30)Positive/negative 
for cross-reactivity
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 19 of 94
(positive/negative) 
* %B/T is % bound radioactivity-labelled insulin 287/Total added radioactivity-labelled 
insulin 287.
4.3.3 Exploratory endpoints
Endpoint title Time Frame Unit
Insulin 287 concentrations, 
evaluated in a population PK 
analysisFrom baseline (V2) to week 
26 (V28)pmol/L
Time in target-range 3.9‚Äì7.8 
mmol/L (70-140 mg/dL) 
measured by flash glucose 
monitoring (FGM) (  
FreeStyle Libre Pro) During the last 2 weeks of 
treatment (week 25 and 26)Time unit
5 Trial design 
5.1 Overall design
This is a 26-week, randomised, double-blind, double-dummy, active-controlled, parallel-group, 
stratified, multicentre, multinational trial with  2 arms comparing the efficacy and safety of 
treatment with insulin 287 once weekly versus insu lin glargine once daily in insulin-naive subjects 
with T2DM inadequately controlled on metformin with or without DPP4i.
Subjects will be randomised in a 1:1 manner to receive once weekly insulin 287 and once daily 
placebo or once weekly placebo and once daily insulin glargine. The randomisation of subjects will be stratified based on use of DPP4i.
The total trial duration for the individual subject will be approximately 33 weeks. The trial includes 
a 2 week screening period, followed by a 26-week randomised treatment period and a 5-week 
follow-up period. 
After screening, all eligible subjects will be randomised (1:1) to insulin 287 or insulin glargine at 
the randomisation visit (V2). During the 26-week treatment period, the subjects will have weekly 
contact with the site either at site visits or by phone. 
After 26 weeks of treatment the subjects will come in for their end-of-tr eatment visit. The end of-
treatment visit will be one week after the last dose of once weekly insulin/once weekly placebo and 
on the day of or the day after the last dose of once daily insulin/once daily placebo.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 20 of 94
The end of-treatment visit will be followed by two follow up visits (V29 and V30). The last follow 
up visit (V30) is scheduled to take place 6 weeks after the last dose of once weekly insulin/once 
weekly placebo and 5 weeks after the last dose of once daily insulin/once daily placebo.
The dose and dosing frequency of metformin with or without DPP4i should not be changed at any 
time during the trial, unless due to safety concerns.
Event adjudication will be performed for major adverse cardiovascular events (MACE) and 
hypersensitivity reactions (see section 9.2.1.1 ).
The overall trial design and visit schedule are outlined in the trial diagram Figure 5-1 and trial 
flowchart (section 2) respectively.
Figure 5-1 Trial Design
5.2 Subject and trial completion
250 subjects will be randomly assigned to trial product. The estimated number of subjects to 
complete the trial (on trial product) is 215.
Trial period completion for a subject:
Trial period completion is defined as when the randomised subject has completed the final 
scheduled visit V30, (‚Äòend of trial' according to the flowchart, section 2).
'Date of trial completion' is the date the subj ect completed the final scheduled visit (V30).
Treatment period completion for a subject: 
Treatment period completion is defined as when the randomised subject has received the required 
treatment, and attended the 'end of treatment' visit (V28) according to the flowchart, section 2
5.3 End of trial definition
The end of the trial is defined as the date of the last visit of the last subject in the trial. 

 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 21 of 94
5.4 Treatment emergent period 
The treatment emergent period represents the period where subjects are considered exposed to trial 
product. It starts at the first date of exposure to randomised treatment and ends at the last follow-up visit (FU2), thus includes a time period after last dose of randomised treatment corresponding to approximately 5 half-lives of insulin 287. Sp ecifically, it ends at one of the following:
!For subjects completing the tr ial: Last follow-up visit (FU2) 
!For subjects who discontinue: Last follow-up visit (FU2) as defined in section 8.1
!For subjects who discontinue, but do not attend FU2 visit: Last dosing day of randomised 
treatment + 5 weeks for glargine, and last dosing day of randomised treatment + 6 weeks for 
insulin 287
5.5 Scientific rationale for trial design
The trial is designed to investigate the effect on glycaemic control, safety and tolerability between a 
once-weekly insulin and a once-daily insulin, while minimising bias of the results. Currently, basal insulins with the longest duration are dosed once d aily. In order to compare to well-established and 
widely used basal insulin with once daily dosing, insulin glargine has been chosen as comparator. 
The treatment arms will be blinded to increase the scientific value of the results as compared to an open design, thus avoiding bias from investigators and subjects. To ensure blinding between the two treatments with different duration of action and dosing frequency, a double-dummy approach is 
applied. The treatment duration of 26 weeks has been chosen as an adequate time to assess effect on 
glycaemic control as well as safety and tolerab ility. This duration will also allow for up-titrating the 
basal insulin as well as a sufficient maintenance period. The first 16 weeks will be defined as the titration period and the following 10 weeks until en d-of-treatment as the maintenance period. The 
treat-to-target approach has been chosen in order to ensure optimal titration of insulin based on self-
measured plasma glucose (SMPG) values with the aim of improving HbA
1cin the period.
Subjects included in the trial will be insulin na√Øv e, but all will use first line treatment metformin. 
Use of DPP4i in addition to metformin is allowed but not a requirement. Subjects will be stratified 
on use of DPP4i to ensure an equal distribution of subjects in both treatment arms. To include a 
more homogenous study population, other oral antidiabetic drugs are not allowed.
Titration of insulin 287 and IGlar are based on three pre-breakfast SMPG values measured on two 
days prior to titration and on the day of the contact.
Furthermore, to collect data to characterise the effect of insulin 287, FGM data will be collected 
during the trial.  
To safeguard subjects, the inclusion and exclusi on criteria defined in this trial will limit the trial 
population to subjects not suffering from underlying di seases other than type 2 diabetes and related 
diseases, such as hypertension or dyslipidaemia. Th is is to avoid compromising the safety of the 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 22 of 94
subjects participating in the trial and to strengthen conclusions regarding the efficacy, safety and the 
PK properties of once-weekly insulin 287.
Furthermore, during the treatment period, the subjects will have weekly contacts with the site either 
at visits to the site or phone contacts and the first 5 administrations of once-weekly insulin 287 or once-weekly placebo will be done at the site. After th e injections at the site, the subjects should stay 
at least one hour for observation. The last follow- up visit is planned to be 6 weeks after last once-
weekly insulin/once-weekly placebo dose allowing appropriate time for wash-out of trial drug, 
following at least 5 half-lives of insulin 287.
Ethical considerations 
All subjects must only be included after a thorough evaluation with regards to defined in- and 
exclusion criteria in order to ensure that sub jects are eligible for trial treatment. Subjects will be 
treated with a treat-to-target insulin regimen anticipated to improve glycaemic control compared totheir pre-trial treatment. To participate in the trial subjects will have to spend some extra time, as 
additional assessments and visits to the clinic are required. Some of the visits will also require that 
the subject is fasting for blood sampling. In case of lack of efficacy of trial product, the subject will 
be prematurely discontinued with reference to  premature discontinuation criteria, section 8.1
The trial products may be associated with adve rse reactions, of which hypoglycaemia is the most 
common. For further information, please refer to the Investigator‚Äôs Brochure for insulin 2877and 
local label for insulin glargine. Relevant precau tions have been implemented in the design and 
planned conduct of the trial in order to minimise the risks and inconveniences of participation in the trial. These precautions include thorough information regarding the correct administration of the trial products and gradual dose adjustment. Furthermore, subjects will be informed about possible 
adverse reactions and inconveniences and will be instructed to contact the investigator in case of 
any concerns regarding the trial participatio n. The double-dummy study design introduces a 
potential risk of mix-up between treatments. To minimise this risk, injections of the weekly insulin 
287/insulin 287 placebo will be performed at the site during the first month while the once daily injections are performed by the subjects at home. To further mitigate the risk, instructions will be 
given to consistently use the same thigh for injection, left for the once weekly injection and right for 
the once daily injection throughout the study period.
5.6 Justification for dose
Insulin glargine will be initiated at 10 units (U) once daily and insulin 287 will be initiated at 70U 
once weekly. One U of insulin 287 has similar glucose lowering effect as one U of a standard 
insulin analogue, such as insulin glargine, and therefore once-weekly dosing corresponds to 7 times the daily dose of the once daily comparator. Starting dose is based on insulin glargine label.
The starting dose is considered to be safe and conservative for insulin na√Øve subjects with type 2 
diabetes. The PK/PD properties of insulin 287 following 5 weeks of once weekly dosing in subjects 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 23 of 94
with type 2 diabetes (trial NN1436-4314) showed  that insulin 287 exposure was well distributed 
across the dosing interval, with a PK profile suitable for once weekly dosing. Insulin 287 was well 
tolerated in subjects with type 2 diabetes and no sa fety concerns were identified after multiple once-
weekly dosing in the dose range of 12 ‚àí24 nmol/kg.
After randomisation at V2, subjects will start on ce daily and once-weekly  injections on the same 
day. This treatment will continue until 25 weeks af ter randomisation. At this time point the last once 
weekly injection must be taken while the once daily injections are taken until 26 weeks after randomisation where the subjects come in for the end of treatment visit (V28). This is due to the longer half-life of Insulin 287. Further details can be found in Appendix 9 , titration guideline.
6 Trial population  
Prospective approval of protocol de viations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
6.1 Inclusion criteria
Subjects are eligible to be included in the trial only if all of the following criteria apply:
1. Informed consent obtained before any trial-r elated activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
2. Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus ‚â• 180 days prior to the day of screening.
4. HbA
1cof 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central laboratory.
5. Stable daily dose(s) for 90 days prior to the day of screening of any of the following anti-
diabetic drug(s) or combination regime(s):
(a) Any metformin formulations ‚â• 1500 mg or maximum tolerated or effective dose 
(as documented in subject's medical record) 
(b) Any metformin formulations ‚â• 1500 mg or maximum tolerated or effective dose 
(as documented in subject medical record) with DPP4i ( ‚â• half of the maximum 
approved dose according to local label or maximum tolerated or effective dose (as documented in subject's medical records) 
6. Insulin na√Øve. However, short term insulin treatment for a maximum of 14 days prior to the day 
of screening is allowed, as is prior insulin treatment for gestational diabetes.
7. Body mass index (BMI) ‚â§ 40.0 kg/m
2
6.2 Exclusion criteria 
Subjects are excluded from the trial if any of the following criteria apply:
1. Known or suspected hypersensitivity to trial product(s) or related products. 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 24 of 94
2. Previous participation in this trial. Participation is defined as signed informed consent. 
3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice). For Czech Republic and Greece, please see Appendix 10 for country specific requirements.
4. Receipt of any investigational medicinal product with in 90 days prior to the day of screening.
5. Any disorder, except for conditions associated w ith type 2 diabetes mellitus, which in the 
investigator‚Äôs opinion might jeopardise sub ject‚Äôs safety or compliance with the protocol.
6. Any episodes of diabetic ketoacidosis within the past 90 days prior to the day of screening and 
between screening and randomisation.
7. Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic 
attack within 180 days prior to the day of sc reening and between screening and randomisation.
8. Presently classified as being in New York Heart Association (NYHA) Class IV.
9. Planned coronary, carotid or peripheral artery revascularisation.
10. Renal impairment measured as est imated Glomerular Filtration Rate  (eGFR) value of eGFR   
<60 ml/min/1.73 m2 as defined by KDIGO 2012 using the CKD-Epi for eGFR calculation*
11. Impaired liver function, defined as Alanine Aminotransferase (ALT) ‚â• 2.5 times or Bilirubin 
>1.5 times upper normal limit at screening*
12. Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic ‚â•180 
mmHg or diastolic ‚â•110 mmHg) at screening.
13. Treatment with any medication for the indication of diabetes or obesity other than stated in the 
inclusion criteria within the past 90 days prior to the day of screening. However, short term 
insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes.
14. Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) 
known to affect weight or glucose metabolism (e.g. treatment with orlista t, thyroid hormones, or 
corticosteroids).
15. Uncontrolled and potentially unstable diabetic r etinopathy or maculopathy. Verified by a 
pharmacologically pupil-dilated fundus examin ation performed by an ophthalmologist or 
another suitably qualified health care provider within the past 90 days prior to screening or in 
the period between screening and randomisation.
16. Presence or history of malignant neoplasms within  the past 5 years prior to the day of screening. 
Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.
*Result from the screening visit a s provided by the central lab.
6.3 Lifestyle restrictions
Not applicable for this trial.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 25 of 94
6.4 Fasting requirements
The subjects should be fasting when attending some of the visits, see flowchart, section 2. 
Fasting is defined as at least 8 hours without food and drink intake, except for water and other 
prescribed medication. Trial product and other glucos e lowering agents should be withheld on the 
day of the fasting visit until blood sampling and body weight (if applicable) have been performed. 
Any other prescribed medication should be taken as usual. If the subject attends a fasting visit in a 
non-fasting state the blood sampling and body weight procedures should be re-scheduled to the next day.
6.5 Screen failures
Screen failures are defined as subjects who consent to participate in the clinical trial but are not 
eligible for participation according to in/exclusion  and/or randomisation criteria. A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure subjects to meet requirements from regulatory authorities. Minimal information includes demography, screen 
failure details, eligibility criteria, and any SAE. A screen failure session must be made in the 
interactive web response system (IWRS). 
Individuals who do not meet the criteria for participation in this trial may not be rescreened. Re-
sampling is not allowed if the subject has failed one of the inclusion criteria or fulfilled one of the 
exclusion criteria related to laboratory par ameters. However, in case of technical issues (e.g. 
haemolysed or lost), re-sampling is allowed for the affected parameters. 
6.6 Randomisation criteria
To be randomised, the randomisation criterion must be answered "yes".
1) Subject able and willing to adhere to the prot ocol including self-admin istered daily  injections 
using vial and syringe based on the Investigator‚Äôs judgment.
7 Treatments
7.1 Treatments administered
!All investigational medical products (IMPs) are listed in table Table 7-1
!Trial product must only be used, if it appears clear and colourless. 
!Trial products must not be dispensed to any person not included in the trial
Table 7-1 Trial products provided by Novo Nordisk A/S
Trial product 
name:NNC0148-0287 C 4200 nmol/mL or placebo 
(IMP, test product or double dummy)Insulin glargine 100 U/mL or placebo
(IMP reference therapy or double dummy)
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 26 of 94
Dosage form: Solution for injection Solution for injection
Route of 
administration:Subcutaneously into the left thigh.
Rotation of injection site on the left thigh is recommendedSubcutaneously into the right thigh . 
Rotation of injection site on the right thigh is recommended.
Recommended 
initial dose.Initial dose 70U.
For details refer to Appendix 9 .Initial dose 10U. 
For details refer to Appendix 9 .
Dosing 
instructions:Once weekly at the same day of the week, 
anytime during the day, preferably at the same 
time of the day.
For details on dose titration. See Appendix 9 , 
Titration Guideline.Once daily anytime of the day, preferabl yat the 
same time every day
For details on dose titration. See Appendix 9 , 
Titration Guideline.
Packaging. 3 mL PDS290 pre-filled pen-injector. 10 ml vial 
!After randomisation at V2, subjects will start once daily and once-weekly injections on the 
same day. During the treatment period, the subjects will have weekly contacts with the site 
either at visits to the site or phone contacts a nd the first 5 administrations of once-weekly 
insulin 287 or once-weekly placebo will be done at the site. After the injections at the site, 
the subjects should stay at least one hour for observation.
!Once daily and once-weekly injections will continue until 25 weeks after randomisation. At 
this time point the last once weekly injection must be taken while the once daily injections 
are taken until 26 weeks after randomisation where the subjects come in for the end of 
treatment visit (V28).
!Subjects must be trained in the use of vial and syringe at V1, by having the subjects inject 
themselves with saline solution at site. If deemed necessary by the investigator, it could be 
considered to have the subjects inject themselves with saline solution at home between V1 and V2. At V2 the ab ility to self-administer daily injections will have to be assessed prior to 
randomisation.
!Subjects must be trained in handling of the PDS290 pre-filled pen-injector at V2.
!Training in handling the pen-injector and vials/syringes must be repeated during the trial as 
needed.
!Subjects should be instructed to discard the injector needle and syringe after each injection 
and store the pen-injector without an injection needle attached. 
!The investigator must document that directions for use (DFU) are given to the subject 
verbally and in writing at the first dispensing visit (V2). Directions for use can be handed 
out as needed at subsequent visits.
7.1.1 Non-investigational medical products
The oral antidiabetic drugs metformin and DPP4i ar e considered as Non Investigational Medicinal 
Products (NIMPs) and hence will not be provided by Novo Nordisk, unless required by local law 
and should be purchased or otherwise delivered to subjects in accordance with the local health plan.
For Slovakia, please see Appendix 10 for country specific requirements.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 27 of 94
7.1.2 Auxiliary supplies
The following will be provided by N ovo Nordisk:
!DFU for PDS290 pre-filled pen-injector and vials
!Needles for PDS290 pre-filled pen-injectors. Only needles provided by Novo Nordisk must 
be used for administr ation of trial product. 
!Syringes for injection of insulin glargine (for use with vial)
!Diary
!Blood glucose (BG) meter and related auxiliaries 
!  FreeStyle Libre Pro supplies (sensor, reader, operator‚Äôs manual and user guides)
Subjects must be instructed in how to use the diary, FreeStyle Libre Pro and BG meter. The 
instruction should be repeated during the trial, as needed. 
For complaints related to the BG meter or the FreeStyle Libre Pro, the investigator must contact the 
device manufacturer‚Äôs technical support according to Operator‚Äôs Manuals provided with the 
devices.
7.1.3 Medical devices
Investigational medical device: 3 mL PDS290 pre-filled pen-injector
The PDS290 pen-injector to be used in this trial has not been approved for marketing. The PDS290 
pen-injector has been documented to be in comp liance with the relevant essential requirements of 
Annex I of the Council directive 93/42/EEC14, and compliance for the indication for use in adults 
with T2D has been verified by the notified body , . In this trial, the PDS290 pen-injector will 
be used in accordance with the verified intended use and indication for use.
The PDS290 pen-injector is not under investigation in that there is no intent to use the results from 
this trial to support a new marketing application or extension of an existing marketing approval.
Training in the 3 mL PDS290 pre-filled pen-injector 
The subjects must be trained according to the direction for use in how to handle the PDS290 pen-
injector. Training must be repeated during the trial at regular intervals in order to ensure correct use 
of the PDS290 pen-injector. 
7.2 Dose modification 
Doses are adjusted according to plasma glucose values as described in Appendix 9 (Titration 
Guideline). 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 28 of 94
7.3 Method of treatment assignment
All subjects will be centrally randomised using IWRS and assigned to the next available treatment 
according to randomisation schedule. Subjects will be stratified based on use of DPP4i. Within each stratum, each subject will be randomly allocated to receive once weekly insulin 287 and once daily placebo or once weekly placebo and once daily insulin glargine.
Trial products will be dispensed at the trial visits summarised in the flowchart, section 2.
7.4 Blinding
This is a double-dummy, double-blinded trial. 
The following trial products will be packed blinde d and are visually identical for the following trial 
product:
!Insulin 287 or once weekly placebo, 3 mL PDS290 pre-filled pen-injector 
!Insulin glargine or once daily placebo, 10 mL vial
The specific trial product for a subject will be assigned using the IWRS. The site will access the 
IWRS before the start and each dispensation of  trial product administration for each subject. 
The IWRS is used for blind-breaking instructions. The blind may be broken in a medical emergency 
if knowing the actual treatment would influence the treatment of the subject. Novo Nordisk will be 
notified immediately after breaking the blind. The date when and reason why the blind was broken 
must be recorded in the source documentation.
Whenever the blind is broken, the person breaking the blind must print the "code break 
confirmation" notification generated by the IWRS and sign and date the document. 
When the blind is broken, the treatment allocation will be accessible to the investigator and the 
Novo Nordisk Global Safety department. If IWRS is not accessible at the time of blind break, the IWRS helpdesk should be contacted. Contact details are listed in Attachment I. 
If the blind has been broken by investigator, the subject must discontinue treatment with trial 
product and a treatment discontinuation session must be completed in IWRS. 
The laboratory responsible for pharmacokinetics  and antibodies analyses and the responsible 
scientific monitor of bioanalysis at Novo Nordisk will have access to the treatment allocation in the IWRS. 
7.5 Preparation/Handling/Storage/Accountability
Only subjects enrolled in the trial may receive trial product and only authorised site staff may 
supply or administer trial product. 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 29 of 94
Storage conditions, in-use conditions and in -use time for trial products will be available on the 
product label and in the TMM. 
!Each trial site will be supplied with sufficient trial products for the trial on an on-going basis 
controlled by the IWRS. Trial product will be distributed to the trial sites according to 
screening and randomisation.
!The investigator must confirm that appropriate temperature conditions have been maintained 
during transit for all trial products received and any discrepancies are reported and resolved 
before use of the trial products.
!All trial products must be st ored in a secure, controlled, and monitored (manual or 
automated) area in accordance with the labelled storage conditions with access limited to the 
investigator and authorised site staff.
!The investigator must inform Novo Nordisk immediately if any trial product has been stored 
outside specified conditions. Additional details regarding handling of temperature deviations 
can be found in the TMM. 
!Trial product that has been stored improperly must not be dispensed to any subject before it 
has been evaluated and approved for further use by Novo Nordisk.
!The subject must return all used and unused trial product including empty packaging 
materials during the trial as inst ructed by the investigator.
!The investigator is responsible for drug accountab ility and record maintenance (i.e. receipt, 
accountab ility and final disposition rec ords).
!Drug accountability should be pe rformed on a pen/vial level and must be documented in the 
IWRS.
!Destruction of trial products can be performed on an ongoing basis and will be done 
according to local procedures after accountability is  finalised by the site and reconciled by 
the monitor. 
!Destruction of trial products must be documented in the IWRS. 
!All returned, expired or damaged trial products (for technical complaint samples see 
Appendix 6 ) must be stored separately from non-allocated trial products. No temperature 
monitoring is required.
!Non-allocated trial products including expired or damaged products must be accounted as 
unused, at the latest at closure of the trial site. 
7.6 Treatment compliance
Throughout the trial, the investigator will remind the subjects to follow the trial procedures and 
requirements to ensure their compliance .The investigator should assess the compliance of the 
subject at each contact (visit or phone contact) by evaluating the glycaemic control and adherence to the visit schedule, completion of the sub ject¬¥s diary, including the SMPG profiles, dose and 
hypoglycaemia reporting. If a subject is found to be non-compliant the investigator will remind the 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 30 of 94
subject of the importance of following the instru ctions including taking the trial products as 
prescribed.
7.7 Concomitant medication
Any medication other than the trial product(s) that the subject is receiving at the time of the first 
visit (V1) or receives during the trial (incl. follow-up visits) must be recorded along with:
!Trade name or generic name
!Indication
!Dates of administration including start and stop dates or continuation 
Concomitant medication (diabetes)
!For metformin and DPP4i (if used), the following additional information must be recorded: 
Start date of current dose and total daily dose. The dose should not be changed at any time 
during the trial, unless due to safety concerns.
!Until end of treatment (V28) only randomised  treatment (trial products and metformin with 
or without DPP4i) are allowed.
!If the investigator chooses to initiate other anti-diabetic medication  or change dose of 
metformin/DPP4i prior to end of treatment (V28), this is defined as ancillary treatment (see 
section 7.7.1 )
!For new anti-diabetic medication prescribed in the follow up period start date of current 
dose and total daily dose must also be recorded.
Changes in concomitant medication must be recorded at each visit. If a change is due to an
AE/SAE , then this must be reported according to Section 9.2.
7.7.1 Ancillary treatment 
Until end of treatment (V28) only randomised  treatment (trial products and metformin with or 
without DPP4i) are allowed. Ancillar y treatment is  defined as any diabetes medication - other than 
randomised treatment (trial products and metformin with or without DPP4i) initiated due to for example safety reasons. It should be registered as concomitant medication (diabetes) in theelectronic case report form (eCRF). 
For subjects not treated with DPP4i prior to the randomisation, initiation of long term us e of DPP4i 
is considered as ancillary treatment. A medication error (see Appendix 4 ) is as such not considered 
as ancillary treatment.
7.8 Treatment after the end of the trial 
When discontinuing trial products, either at the scheduled end of treatment visit (V28) or if trial 
product is discontinued, the subject should be transferred to a suitable marketed product at the 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 31 of 94
discretion of the investigator. If the switch to post-trial treatmen t includes a new insulin treatment, 
please refer to the titration guideline Appendix 9 for more information.
8 Discontinuation/Withdrawal criteria
All efforts should be made to keep subjects on trial products. 
The subject may be discontinued at any time during the trial at the discretion of the investigator for 
safety, behavioural, compliance or administrative reasons. 
Efforts must be made to have the subjects, who discontinue trial product,  attend the end of treatment
visit corresponding to V28 as soon as possible after discontinuation of trial product (preferably the same day) to collect the required data for the analysis of the primary endpoint. The two follow up 
visits must also be performed. FU1 must be scheduled at least 2 weeks (+3 days) after and FU2 
must be scheduled 5 weeks (+3 days) after discontinuation of the trial product respectively.
Once the two follow-up visits after discontinuation  of trial product are completed the subject should 
be contacted by phone every 4 weeks. Information  on antidiabetic medication must be collected and 
recorded in the eCRF. Phone contacts must be documented in the medical record and in the eCRF. 
The subject should finally come in for the discontinuation follow-up visit (V28A), 26 weeks after randomisation and have the assessments performed stated in the flow chart (section 2).
Final drug accountability must be done once the subject has discontinued the trial product and the 
premature discontinuation must be recorded in the IWRS through a treatment discontinuation 
session.
The reason for the premature discontinuation of trial product must be recorded in the eCRF.
Only subjects who withdraw consent will be considered as withdrawn from the trial. See section 8.2
8.1 Discontinuation of trial treatment
The subject must be discontinued from trial product, if the following applies:
1. Safety concern related to trial product or unacceptable intolerability
2. Pregnancy
3. Intention of becoming pregnant
4. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product.
5. Lack of efficacy, defined as fulfilment of all4 criteria below:
!No reduction in HbA 1cmeasured by central laboratory from randomisation (V2)  to visit 10, 
or to visit 14, or to visit 18, or to visit 22 or to visit 26 AND
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 32 of 94
!The pre-breakfast SMPG readings on 3 consecutive days higher than 240 mg/dL (13.3 
mmol/L) within the last two weeks period despite appropriate dose adjustments AND
!A confirmatory fasting plasma glucose (FPG) exceeding 240 mg/dL (13.3 mmol/L)
measured by central laboratory. The subject should come in for an unscheduled visit as soon 
as possible (within one week). The next scheduled visit should not be awaited AND
!No treatable intercurrent cause (e.g. non-compliance) for the hyperglycaemia at the 
investigator‚Äôs judgment
See the flowchart 2for data to be collected at the time of treatment discontinuation and follow-up 
and for any further evaluations that need to be completed.
The primary reason for discontinuation of trial produ ct must be specified in the eCRF, and final 
drug accountability must be performed. A treatment discontinuation session must be made in the 
IWRS.
A subject who does not fulfil the eligibility (inclu sion/exclusion/randomisation) criteria must not be 
randomised. Randomisation in violation of any of the eligibility criteria is Good Clinical Practice 
(GCP) non-compliance and must be reported to the sponsor without delay. This will be handled as 
an important protocol deviation, and the IEC/IRB and regulatory authorities must be notified according to local requirements. If there is no safety concerns, trial treatment may be continued or resumed at the discretion of the investigator after agreement with the sponsor's global medical 
expert.
8.2 Withdrawal from the trial
A subject may withdraw consent at any time at his/her own request.
If a subject withdraws consent, the investigator must ask the subject if he/she is willing, as soon as 
possible, to have assessments performed according to V28 and come in for the follow up visits 
(V29 and V30). See the flowchart 2for data to be collected. 
Final drug accountability must be performed even if the subject is not able to come to the trial site. 
A treatment discontinuation session must be made in the IWRS. 
If a subject withdraws from the trial, he/she ma y request destruction of any samples taken and 
samples not tested, and the investigator must document this in the medical record.
If the subject withdraws consent, Novo Nordisk may retain and continue to use any data collected 
before such a withdrawal of consent.
Although a subject is not obliged to give his/her reason(s) for withdrawing, the investigator must 
make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. Where the reasons are obtained, the primary reason for withdrawal must be specified in the eCRF.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 33 of 94
8.2.1 Replacemen t of subjects
Subjects who discontinue trial product or withdraw from trial will not be replaced.
8.3 Lost to follow-up
A subject will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the trial site. 
The following actions must be taken if a subject fails to return to the trial site for a required visit:
!The site must attempt to contact the subject and reschedule the missed visit as soon as 
possible and counsel the subject on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subject wishes to and/or should continue in the trial.
!Before a subject is deemed lost to follow-up, the investigator must make every effort to 
regain contact with the subject (where possible, at least three telephone calls and, if necessary, a certified letter to the subject's last known mailing address or local equivalent 
methods). These contact attempts should be documented in the subject's source document.
!Should the subject continue  to be unreachable, he/she will be considered to have withdrawn 
from the trial with a primary reason of lost to 'follow-up'. 
9 Trial assessments and procedures
!Trial procedures and their timing are summarised in the flowchart 2. 
!Informed consent must be obtained before any trial related activity, see Appendix 3 .
!All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all eligibility criteria. 
!The investigator will maintain a screening log to record details of all subjects screened and 
to confirm eligibility or record reason for screen failure, as applicable.
!At screening, subjects will be provided with a card stating that they are participating in a 
trial and giving contact details of relevant trial site staff. 
!Adherence to the trial design requirements, including those specified in the flowchart, is 
essential and required for trial conduct. 
!Review of completed diaries, electrocardiograms  (ECGs), laboratory reports, eye and 
physical examinations must be documented either on the documents (by signing and dating) or in the subject's source documents. If clarification of entries or discrepancies in the diary is 
needed, the subject must be questioned and a conclusion made in the subject's source documents. Care must be taken not to bias the subject.
!Repeat samples may be taken for technical issues and unscheduled samples or assessments 
may be taken for safety reasons. Please refer to Appendix 2 for further details on laboratory 
samples.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 34 of 94
!Source data of clinical assessments performed and recorded in the eCRF must be available 
and will usually be in the subject‚Äôs medical records. Additional recording to be considered source data includes, but is not limited to diar y data, laboratory reports, Libre Pro data, BG 
meter, pictures and ECG recordings. 
9.1 Efficacy assessments
Planned time points for all efficacy assessments are provided in the flowchart 2.
9.1.1 Self-measured plasma glucose 
At the screening visit (V1) , subjects must be provided with a BG meter including auxiliaries and a 
diary as well as instructions for use. The subjects must be instructed in how to use the devices and the instruction should be repeated at regular intervals as indicated in the flowchart 2.
The BG meters use test strips calibrated to pl asma values. Therefore, all measurements performed 
with capillary blood are automatically calibrated to plasma equivalent glucose values, which will be 
shown on the display. 
The BG meter provided by Novo Nordisk must  be used for the measurements required in the 
protocol, as described in the flow chart 2.
Subjects should be instructed in how to record the results of the SMPG values in the diaries. The 
record of each SMPG value should include date, time and value. All data from the diary must be transcribed into the eCRF during or following the contact. If obtained via phone and a discrepancy is later detected, the values in the eCRF must be corrected.
Occasional review by the investig ator of the BG meter values stored in the memory of the BG m eter 
and correct reporting of these in the diary is advised in order to ensure adequacy of the data reported in the trial database .
Selected titration data (e.g. certain SMPGs and insulin doses) will only be used during the trial for 
central titration surveillance, to ensure compliance with the titration guideline Appendix 9 . Only 
SMPGs obtained as part of the 9-point profiles will be reported in the clinical trial report (CTR).
Once daily pre-breakfast SMPG
Subjects should perform daily pre-breakfast SMPG from randomisation visit (V2) to end of 
treatment visit (V28). These SMPG values should be performed in a fasting c ondition.
9-point SMPG profile
Subjects will be instructed to perform 9-point profiles in the week prior to visits as specified in 
section 2, on a day where the subject does not anticipate unusu al strenuous exercise. 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 35 of 94
The SMPG values obtained should be recorded in the diary (including actual clock time and date of 
measurement) according to the time points listed below: 
!Before breakfast 
!90 minutes after the start of breakfast
!Before lunch
!90 minutes after the start of lunch
!Before main evening meal (dinner)
!90 minutes after the start of main evening meal (dinner)
!At bedtime
!At 4 am
!Before breakfast the following day
SMPG values measured before breakfast should be performed in a fasting condition. 
The measurements will be used to evaluate the glucose profile.
9.1.2 Insulin  dose
During the trial, starting at the randomisation visit (V2), subjects must be instructed to report date, 
dose and time of once weekly and date and dose of once daily insulin in the diary. 
The recommended insulin doses will be calcu lated by the investigator b ased on recommendations 
from the Titration Guideline (see Appendix 9 ). At each visit/phone contact the Investigator will 
titrate the subjects by making prescribed dose adjustments based on the recommendation from the 
diary, if applicable.
The Investigator must record the following in the eCRF:
!Date, dose and injection time of once-weekly insulin/placebo 
!Date and dose of once-daily insulin/placebo:
oFrom V2 to V26: Insulin glargine/insulin  glargine-placebo doses must be recorded 
two days prior to and on the day of the visit/contact.
oFrom V26 to V28: Insulin glargine/insulin glargine-placebo doses must be recorded 
every day.
!Prescribed doses of once-weekly and once- daily insulin/placebo i.e. what the investigator 
tells the subject to take
!Reason for deviation from the recommended dose, if needed
For dosing of anti-diab etic medication prescribed in the fo llow up period please see section 7.7
9.1.3 Flash Glucose Monitoring
In order to evaluate the effect on glycaemic control at different time points during the trial, subjects 
will have FGM profiles generated 5 times during the trial. Please refer to the flowchart in section 2.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 36 of 94
The FGM system used in this trial will be the FreeStyle Libre Pro system which consists of two 
parts: 
!the sensor, applied on the back of the subjects‚Äô upper arm
!the reader, a hand held device kept at site and used to download data stored on the sensor
The sensor is pre-calibrated during manufacturing and requires no finger stick calibration during 
use. The sensor measurements performed in  the interstitial fl uid are au tomat ically calibrated to 
plasma equivalent glucose values, which will be shown on the display of the reader upon download of sensor data. 
The FGM readings will be blinded to the subject as the reader will be kept at site.  
The FGM values generated should not be used for insulin dose titration and/or hypoglycaemic 
episodes reporting.
9.1.3.1 FGM Reader setting
Each site will receive 2 readers; one to activate all subjects‚Äô sensors and download of their data and 
one as backup. 
The FGM reader must be set up before use. The set up includes:
!Date and time setting
!Entry of the target glucose range. The range 3.9‚Äì7.8 mmol/L (70-140 mg/dL) should be 
used.
Time and date as well as level of  battery should be ve rified each time the reader is used. 
9.1.3.2 Fitting and removal of the FGM sensor
The sensor must be applied on the back of the upper arm of the subjects, using the sensor applicator 
as described in the Operator‚Äôs manual. When applied, a thin, flexible and sterile fibre is inserted just 
under the skin of the subjects, allowing the measurement of glucose concentration in the interstitial 
fluid. 
The sensor must be activated by holding the site reader within 4cm (1.5inch) of the sensor. 
Successful start of the sensor must be checked as described in the Operator‚Äôs manual.
The sensor will store the subject‚Äôs glucose readings every 15 minutes for up to 14 days. 
For further information on preparing, fitting, and removal of the FGM system, please refer to the 
Operator‚Äôs manual.
If a subject withdraws consent during one of the FGM periods, a site visit must be scheduled in 
order to remove the sensor and download data to the reader. 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 37 of 94
9.1.3.3 Duration of FGM periods
The sensor has an in-use period of 14 days and will automatically stop recording data 14 days after 
insertion and activation. 
Subjects must aim to use the sensor for 14 days.
In cases where the sensor is dislodged prematurely, the subject must be fitted with a new sensor as soon as possible. Additional fitting visit at site will not be considered an unscheduled visit. 
9.1.3.4 Wearing of the FGM sensor
Before each FGM periods, subjects must be instructed to follow the recommendations and 
limitations described in the Operator‚Äôs manual and user guide while wearing the FGM sensor.
Subjects must be instructed to remove the FGM sensor prior to any X-ray, Computerised 
Tomography (CT) scan, high-fre quency electrical heat (diathermy) treatment or magnetic resonance 
imaging (MRI).
9.1.3.5 Transfer of FGM data
Data stored on the sensor must be downloaded at the site by holding the reader within 4cm (1.5inch) 
of the sensor. Data on the reader device must then be uploaded to the provided FGM Software program that allows upload of the FGM data from the reader, following the instructions from the 
user guide provided to sites. The upload will be documented by the system directly.
The following information must be recorded and transferred into the eCRF for every FGM period:
!Serial number of the FGM sensor
!Sensor fitting date and time
!Sensor removal date and time
9.1.4 Clinical e fficacy laboratory assessments
All protocol-required laboratory assessments, as defined in Appendix 2 , must be conducted in 
accordance with the flowchart and the laboratory manual.
9.2 Adverse events
The definitions of AEs and SAEs can be found in Appendix 4 .
The investigator is responsible for detecting, documenting, recording and following up on events 
that meet the definition of an AE or SAE.
9.2.1 Time period and f requency for collecting AE and SAE information
All AEs will be collected from the first trial-r elated activity after obtaining informed consent and 
until the second follow-up visit (V30) ,at the time points specified in the flowchart. 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 38 of 94
All SAEs will be recorded and reported to Novo Nordisk or designee within 24 hours, as indicated 
in Appendix 4 . The investigator must submit any updated SAE data to Novo Nordisk within 24 
hours of it being available.
Investigators are not obligated to actively seek for AE or SAE in former trial subjects. However, if 
the investigator learns of any SAE, including a death, at any time after a subject has been 
discontinued from/comp leted the trial, and the investigator considers the event to be 
possibly/probably related to the investigational trial product or trial participation, the investigator must promptly notify Novo Nordisk.
The method of recording, evaluating and assessing  causality of AE and SAE and the procedures for 
completing and transmitting SAE reports are provided in Appendix 4 .
Timelines for reporting of AEs and even ts for adjudication are listed in Figure 9-1 .
Some AEs require additional data collection via a specific event form. This includes medication 
errors and hypoglycaemic episodes observed during the trial. The relevant specific events are listed 
in Table 9-1 and the reporting timelines in Figure 9-1 .
Figure 9-1 Decision tree for determining the event type and the respective forms to 
complete with associated timelines:
AE identifiedIs the event to be 
adjudicated
AE form‚â§  24 hours
SIF ‚â§5 calendar days
Sig n off‚â§ 7 calendar days
Is the AE serious or 
non-serious?
AE form*Is the AE li sted as 
requiri ng a Specific Event 
Fo rm to be com pleted ?
Source data collection 
and upoad to Event 
Adjudiction System ‚â§4 
weeks
Non-seriousSe ri ou s
NoYes
No additional actionNo
Specific event form
For SAE:
‚â§14 calendar days
Yes
Timelines are from the awarenes s of an AE .
Queries and follow-up reques ts to be resolved ‚â§14 calendar days.
AE: Adverse  Events, SA E: Se rious Adverse Events , SIF: Safety Information Form
* Non-serious hypoglycaemic episodes should be reported on a dedicated 
hypoglycaemic form only.
No additional action
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 39 of 94
Table 9-1 AEs requiring additional data collection (via specific event form) and events for 
adjudication:
AE requirin g 
additional data 
collection via event 
specific form (Appendix 4 )AE for ad judication 
requiring source 
document upload to 
Event Adjudication System (EAS)
(Section 9.2.1.1 , 
Appendix 4 and Event 
Adjudication Manual )
Acute coronary syndrome X
Cerebrovascular event X
Heart failure X
Death X
Hypersensitivit y X
Injection site reactions X X
Medication error X
Hypoglycaemic episodeaX
aRefer to Section 9.2.6 for reporting details
For details about specific event forms, see Appendix 4
9.2.1.1 Event for adjudication
Event adjudication will be performed for adverse events in randomised subjects. The list of events 
for adjudication can be found in Table 9-1 and the reporting timelines in Figure 9-1 . These events 
are reviewed by an independent external event adjudication commit tee (EAC) in a blinded manner;
refer to Appendix 3 for further details.
There are 3 ways to identify events relevant for adjudication as described below:
1) Investigator-reported events for adjudication: 
!All AEs reported with a relevant AE category ( Table 9-1 ) selected based on 
predefined criteria ( Appendix 4 )
!All AEs reported with a fatal outcome
2) Preferred term (PT) search (standardised screening): 
!All AEs recorded in the eCRF but not directly reported by the investigator as 
requiring adjudication, will undergo screening to identify potential events for 
adjudication.
3) Event Adjudication Committee (EAC)-identified events: 
!During review of source documents provided for another event for adjudication, the 
EAC may identify additional events in scope  for adjudication that were not initially 
reported by the investigator. In these instances , the investigator will be notified of the 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 40 of 94
newly identified event and has the option to report the EAC-identified event. 
Regardless of whether the investigator decides to report the event, it will undergo 
adjudication. 
For all the scenarios listed above, investigator must collect copies of all relevant source documents 
specific to the event type as outlined in the Ev ent Adjudication Site Manual. All source documents 
should be labelled with trial ID, subject number and AE number, anonymised of personal identifiers
and uploaded to the EAS as soon as possible and preferably within 4 weeks according to instructions in the Event Adjudication Site Manu al. Specific labelling requirements apply to digital 
pictures (see section 9.4.6.1 and the Event Adjudication Site Manual for details). All follow up 
regarding source documents will be handled in the EAS. If no, or insufficient source documents are 
provided to the adjudication supplier, the investigator can be asked to complete a clinical narrative 
to be uploaded to the EAS.
If new information related to a reported event where source documents have previously been 
provided b ecomes available, it is the responsibility of the investigator to ensure that the new 
information is reflected in both the eCRF and uploaded to the EAS.
The assessments made by both the EAC and the investigator will be analysed and included in the 
clinical trial report.
9.2.2 Method of detecting AEs and SAEs
Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non 
leading verbal questioning of the subject is the preferred method to inquire about events.
9.2.3 Follow-up on AEs and SAEs
After the initial AE/SAE report, the investigat or is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs, will be followed until resolution, stabilisation, or if the event is otherwise explained (e.g. chronic condition) or the subject is lost to follow-up (as defined in Section 8.3). Further information on follow-up procedures is given in Appendix 4 .
9.2.4 Regulatory rep orting requirements for SAEs
Prompt notification by the investigator to Novo Nordisk of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of subjects and the safety of a trial product under clinical investigation are met. 
Novo Nordisk has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a trial product under clinical investigation. Novo Nordisk will comply with country-specific regulatory requirements relating to safety reporting to the 
regulatory authori ty, IRB/IEC, and investigators.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 41 of 94
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions
(SUSARs) according to local regulatory requirements and Novo Nordisk policy and forwarded to 
investigators as necessary.
An investigator who receives an investigator safety report describing a SAE or other specific safety 
information (e.g. summary or listing of SAEs), from Novo Nordisk will review and then file it 
along with the investigator's brochure and will notify the IRB/IEC, if appropriate according to local 
requirements.
9.2.5 Cardiovascular and death events
Cardiovascular and death events will be handled and reported according to AE/SAEs description in 
Section 9.2.1 .
9.2.6 Disease-related events and/or disease-related outcomes not qualifying for standard
AE collection
The following Disease-Related Event (DRE) is common in subjects with T2DM and can be 
serious/life threatening:
!Hypoglycaemic episodes
Definitions, classification and reporting requirements are described in Appendix 8 . 
Hypoglycaemia
Non-serious hypoglycaemia must be reported on a hypoglycaemic episode form.
If the hypoglycaemic episode fulfils the criteria for an SAE then in addition to the above, an AE 
form and a safety information form must also be filled in. One AE form and safety information 
form can cover several hypoglycaemic episode forms, if the subject has not recovered between the episodes.
9.2.7 Pregnancies a nd associated adverse events
Details of pregnancies in female subjects will be collected after the first-trial-related activity after 
obtaining informed consent and until the pregnancy outcome and the new born infant is one month of age.
If a pregnancy is reported in female subjects, the investigator should inform Novo Nordisk within 
14 calendar days of learning of the pregnancy a nd should follow the procedures outlined in 
Figure 9-2 and Appendix 5 . 
Pregnancy outcome should be documented in the subject's medical record. Abnormal pregnancy 
outcome (e.g. spontaneous abortion, foetal death, stillbirth, congenital anomalies and ectopic 
pregnancy) is considered an SAE.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 42 of 94
Maternal form 1b
‚â§14 calendar days after birthMaternal form 1a
‚â§14 calendar daysAfter birth/
termination 
of pregnancy
No additional 
action Normal outcome Maternal form 2 ‚â§14 calendar days
Paternal form*1‚â§14 calendar days Abnormal outcome 
Pre gnanc y 
verified
*1 Further information collected on Paternal form for male partners of 
female subjects requires signing of specific informed consent .
AE/SAEs in connection with the pregnancy and in the foetus/newborn 
should follow the timelines in Figure 9.1.Prior to 
birth or 
pregnancy 
terminati on For female subjects
Figure 9-2 Decision tree for determining the forms to complete with associated timelines 
for pregnancy. 
9.2.8 Medical device in cidents (including malfunctions)
Section not applicable for this trial. Refer to technical complaints in Section 9.2.9 .
9.2.9 Technical complaints 
The investigator must assess whether a technical complaint is related to an AE.
The definitions and reporting process for technical complaints can be found in Appendix 6 .
Timelines for reporting technical complaints are listed in Figure 9-3 .
Technical complaint form: ‚â§ 24 hours 
AE form: ‚â§ 24 hours 
SIF:‚â§ 5 calendar days
Is it related  
to an SAE?
Technical complaint 
identifiedIs it related
to an AE?Yes
NoTechnical complaint form
‚â§ 5 calendar daysTechnical complaint form: 
‚â§ 5 calendar days
AE form: ‚â§ 5 calendar daysNoYes
AE: Adverse Event, SAE: Serious Adverse Event ,  SIF: Safety Information Form
Figure 9-3 Decision tree for determining the forms to complete with associated timelines 
for technical complaints. 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 43 of 94
9.3 Treatment of overdose
The overdose must be reported as a medication error. Refer to Section 9.2.1 for further details.
In the event of an overdose, the investigator shoul d closely monitor the s ubject for over dose-related 
AE/SAE and laboratory abnormalities until the blood glucose is normalised and (or) signs/symptoms has been relieved. 
The administration of insulin, including an overdose of insulin, may result in hypoglycaemia. 
Symptoms usually occur suddenly and may in clude cold sweat, nervousness or tremor, anxious 
feelings, unusual tiredness, confusion, difficult y in concentration, excessive hunger, temporary 
vision changes, headache, nausea and palpitation. Prolonged or severe hypoglycaemia can lead to a 
loss of self-control, spasms, and/or unconsciousness and, in extreme cases, death.  As with all long-
acting insulin preparations, their prolonged effect may delay recovery from a hypoglycaemic episode. 
A specific overdose for insulin 287 cannot be defined; however, hypoglycaemia may develop over 
sequential stages if the doses administered are too high relative to the subject‚Äôs requirements:
!Mild hypoglycaemia can be treated by oral administration of glucose or sugary pr oducts.
!Severe hypoglycaemia, where the subject is not able to treat him/herself, can be treated by 
glucagon (0.5 to 1 mg) given intramuscularly or s.c. by a trained person, or by glucose given 
intravenously by a medical professional. Glucose must also be given intravenously, if the subject does not respond to glucagon within  10-15 minutes. If the subject has been 
unconscious, administration of oral carbohydrates is recommended for the subject upon 
regaining consciousness, in order to prevent a relapse.
Decisions regarding dose interruptions or modifications will be made by the investigator based on 
the clinical evaluation of the subject.
For more information on overdose, also consult the current version of IB for insulin 287 and 
Summary of Product Characteristics for insulin glargine.
8
9.4 Safety assessments
Planned time points for all safety assessments are provided in the flowchart 2.
A concomitant illness is any illness that is present at the start of the trial (i.e. at the first visit) or 
found as a result of a screening procedure or other trial procedures performed before exposure to trial product. 
Medical history is a medical event that the subject has experienced in the past. Only relevant 
concomitant illness and medical history as judge d by the investigator should be reported. 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 44 of 94
The information collected for concomitant illness and medical history should include diagnosis, 
date of onset and date of resolution or continuation, as applicable.
In case of an abnormal and clinically significant finding, the investigator must record the finding on 
the Medical History/Concomitant Illness form if it is present at screening. Any new finding 
fulfilling the AE definition (see Appendix 4 ) during the trial and any clinically significant 
worsening from baseline (V2) must be reported as an AE (see Section 9.2).
9.4.1 Physical e xaminations
!A physical examination will include assessments of:
oHead, ears, eyes, nose, throat, neck
oCardiovascular system
oRespiratory system
oGastrointestinal system including mouth
oMusculoskeletal system 
oCentral and peripheral nervous system
oSkin 
!Body measurements will also be measured and recorded as specified in the flowchart.
oBody weight should be measured in kilogram (kg) or pounds (lb) without coat and 
shoes wearing only light clothing. Body weight will be recorded to one decimal.
oBody weight should be assessed with th e same equipment throughout the trial, if 
possible. 
oHeight should be assessed without shoes. Height is measured in centimetres (cm) or 
inches (in) at screening visit (V1) and recorded to the nearest whole number
oFrom the body weight and height th e BMI will be calculated in the eCRF.
!Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
9.4.2 Vital signs
!Pulse rate as well as diastolic and systolic blood pressure will be assessed.
!Blood pressure and pulse measurements should be preceded by at least 5 minutes of rest for 
the subject in a quiet setting without distractions (e.g. television, cell phones).
!Blood pressure at screening will consist of 3 diastolic and systolic blood pressure 
measurements with intervals of at least 1 minute. All three readings must be entered in the eCRF and the average of the 3 blood pressure readings will be calculated in the CRF. At the 
subsequent visits, the blood pressure should only be measured once.
!Blood pressure and pulse measurements will be assessed with a completely automated 
device. Manual techniques will be used only if an automated device is not available.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 45 of 94
9.4.3 Electrocardiograms
!A 12-lead ECG must be performed by the inve stigator or delegated staff as outlined in the 
flowchart, section 2using an ECG machine that automatically calculates the heart rate and 
measures PR, QRS, QT and QTc intervals. 
!The ECG must be interpreted, signed and dated by the investigator to verify that the data has 
been reviewed. 
!The ECG at screening must be done at the latest at V2 and the results interpreted by the 
investigator before randomisation in order to determine the eligibility of the subject. 
9.4.4 Eye examination 
Subjects with uncontrolled and potentially unstable diabetic retinopathy or maculopathy are not 
eligible as this indicates retinopathy that has recen tly progressed to a level that requires intervention 
or is approaching intervention, but has yet to be brought under control. 
Results of an eye examination performed by an ophthalmologist or another suitably qualified health 
care provider must be available and evaluated by the investigator before randomisation to assess 
eligibility. The eye examination should be pe rformed as a fundus photogra phy (e.g. 2- field 60 
degree or better, colour or red-free)  or by slit-lamp biomicroscopy examination (e.g. using a pre-
corneal or corneal contact lens examination) and performed with pharmacologically dilated pupils.
If the subject had such an eye examination performed within 90 days prior to screening, the 
investigator may base his/her evaluation upon the results of that examination. The examination must 
be repeated before randomisation if the subject has experienced worsening of visual function since the last examination. If the applicable eye examination was performed before the subject signed the informed consent form, it must be documented that the reason for performing the examination was 
not related to this trial.
After randomisation an eye examination performed according to above must be performed as per 
the flowchart in section 2.  The investigator should indicate the outcome of each eye examination. 
Relevant findings prior to randomisation must be recorded as concomitant illness/medical history. 
While relevant findings occurring after randomisation should be reported as an AE, if applicable 
according to section 9.2.
9.4.5 Clinical safety la boratory assessments
All protocol-required laboratory assessments, as defined in Appendix 2 , must be conducted in 
accordance with the laboratory manual and the flowchart 2.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 46 of 94
9.4.6 Immunoge nicity assessments  
Blood samples to be analysed for se rum antibodies against insulin 287 or insulin gla rgine will be 
drawn at pre-specified time points according to the flowchart in section 2. For details on blood 
sampling, serum preparation, storage, labelling and shipments please refer to the laboratory manual. 
Samples from the insulin 287 arm of the study w ill be analysed for anti-insulin 287 antibodies, and 
samples from the comparator arm will be analysed for anti-insulin glargine antibodies. Confirmed 
anti-insulin 287 or anti-insulin glargine antibody positive samples will have an antibody titre value determined, and will be further tested for cross-reactivity to endogenous insulin.
Residual anti-drug antibody samples may be used  for exploratory investigation of antibodies or 
further development of anti-insulin antibody assays.
9.4.6.1 Assessments in case of suspicion of hypersensitivity reaction to trial product
Subjects and investigators will be instructed to detect signs and symptoms of hypersensitivity 
reactions: 
!Local reactions, including injection site reactions and 
!Systemic reactions, including anaphylaxis
In the event of a hypersensitivity reaction:
!The subject should contact the site for advice on further action as soon as possible.
!Treatment should be provided by the investigator according to local clinical practice.
Digital pictures
!The investigator or the subject should take dig ital pictures of the hype rsensitivity reaction at 
time of identification and thereafter as often as judged necessary by the investigator. 
oThe pictures should include subject identification number, date and time, time after 
dosing and a ruler for scaling. All pictures should be stored as part of source 
documentation at site.
Additional blood samples
In the event of a systemic hypersensitivity reaction (defined in Appendix 4 ), as judged by the 
investigator, the subject should be called in as soon as possible to have additional blood samples 
taken in order to analyse the following parameters: 
!Tryptase (optimal 0.5 ‚Äì 2 hours post reaction)
!Total IgE
!Anti-NNC0148-0287 IgE antibodies 
!Anti-NNC0148-0287 binding antibodies
!Histamine release (basophil) assay 
!Anti-human insulin IgE antibodies
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 47 of 94
The blood sampling should be repeated 2 ‚Äì 4 weeks following the systemic hypersensitivity 
reaction. The results will be provided from the centr al laboratory and should be included in the 
documentation provided for event adjudication on the systemic hypersensitivity reaction.
9.5 Pharmacokinetics 
Blood samples will be used to evaluate the pharm acokinetics (PK) of insulin 287. PK samples will 
be collected at the visits outlined in the flowchart, section 2. The investigator must record the exact 
date and clock time for blood sampling in the eCRF. 
Each PK sample will be divided into 2 aliquots (one for pharmacokinetics and one for backup,). The 
back-up sample may be used to evaluate safety or efficacy aspects that address concerns arising during or after the trial.
Procedures for sampling, handling, storage, labelling, and shipments of the specimens must be 
performed in accordance with the laboratory manual. 
Bioanalysis of insulin 287 samples will be performed at a special laboratory using a validated
15, 16
Luminescent Oxygen Channelling Immunoassay (LOCI) with a range of 500 ‚Äì 100.000 pmol/L. 
The exact method will be described in a bioanalytical report. 
9.6 Pharmacodynamics 
Not applicable for this trial.
9.7 Genetics 
Not applicable for this trial.
9.8 Biomarkers 
Not applicable for this trial.
10 Statistical considerations
10.1 Sample size determination The primary estimand is defined as the treatment difference in change in HbA
1cfrom bas eline to 
week 26 between once weekly insulin 287 and once daily IGlar for all randomised subjects, if all subjects had adhered to treatment and did not receive ancillary treatment. This is a ‚Äúhypothetical‚Äù 
estimand. This estimand aims to reflect the treatment effect for subjects that are actually able to take 
the drug during the intended treatment period. With the aim of evaluating proof of concept this estimand is considered relevant.
The sample size is determined such that the width of the two-sided 95% confidence interval (CI) for 
the treatment difference assuming normally distributed data in change from baseline to 26 weeks in 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 48 of 94
HbA 1cis 0.5%-point. The standard deviation (SD) is expected to be 1.0%-point for all treatment 
arms based on observations with IGlar in insulin na√Øve T2DM trials (NN1250-3579, NN1250-3643 
and NN1250-3672). A total of 246 subjects will ensure the required width of the 95% CI. The total number of subjects to be randomised is rounde d from 246 to 250 with 125 in each treatment arm.
The required width of the confidence interval is independent of the choice of estimand and 
sensitivity analyses since all randomised subjects will contribute to all analyses. The SD is assumed 
to be 1.0 based on observations from finalised clinical trials with IGlar in insulin na√Øve T2DM subjects. Since the assumed SD of 1 is to the conservative side it is assumed that the SD will not be further increased by the choice of estimand.
Table 10-1 displays sample sizes for various alternative standard deviations and widths of the 95% 
CI.
Table 10-1 Sample size for various standard deviations and widths of the confidence 
interval
Width of the 95% CI
SD 0.40 0.50 0.60
0.9 312 200 140
1.0 384 246 172
1.1 466 298 208
Sample size is computed for 1:1 randomisation. SD: standard deviation.
10.2 Definition of analysis sets
The following analysis sets are defined in accordance with the International Council for 
Harmonisation (ICH)-E9 guidance17.
!Full Analysis Set (FAS): includes all randomised subjects. In exceptional cases, subjects 
may be eliminated from the full analysis set. In such cases the elimination will be justified 
and documented. The s tatistical evaluation of the FAS will follow the i ntention-to-treat 
(ITT) principle and subjects will contribute to the evaluation ‚Äúas randomised‚Äù.
!Safety Analysis Set (SAS): includes all subjects receiving at least one dose of the 
investigational product or comparator. Subjects in the safety set will contribute to the 
evaluation ‚Äúas treated‚Äù.
Randomised subjects who are lost to follow up and where no exposure information of the 
investigational product or comparators is available after randomisation will be handled as unexposed.
The on-treatment observation period is defined as  the period from date of first dose of randomised 
Investigational Medicinal Product (IMP) until the end of the treatment emergent period.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 49 of 94
The in-trial observation period is defined as the period from date of randomisation and until last 
scheduled subject-site contact (i.e. the end date is the last site/phone visit).
Before data are released for statistical analysis, a review of all data will take place to identify 
protocol deviations that could potentially affect the results. Any de cision to exclude any subject or observation from the statistical analysis is the jo int responsibility of the members of the sponsor 
study group. The subjects or observations to be excluded, and the reasons for their exclusion must 
be documented and signed by those responsible before database lock. The subjects and observations excluded from analysis sets, and the reason for this, will be described in the clinical trial report. 
10.3 Statistical analyses
If necessary, a SAP may be written in addition to the protocol, including a more technical and 
detailed elaboration of the statistical analyses. The SAP will be finalised before database lock.
Novo Nordisk will analyse and report data from all trial sites together.
All efficacy endpoints will be summarised using the full analysis set (FAS) and safety endpoints 
will be summarised using the safety analysis set (SAS). All statistical analyses of efficacy and safety endpoints will be based on the FAS unless otherwise specified.
Endpoints are summarised by arithmetic mean, SD, median, and minimum and maximum value. 
Selected endpoints, e.g. endpoints that are analysed log-transformed, will be reported with 
geometric mean and coefficient of variation in place of mean and SD. For measurements over time, mean values will be plotted to explore the trajectory over time. ‚ÄòOn-treatment‚Äô observed data will be used as the basis for plotting data if not otherwise specified. Mean profile for HbA
1cwill be plotted 
by time of treatment discontinuation and treatment in order to investigate discontinuation patterns. 
Data obtained after treatment discontinuation or initiation of ancillary treatment w ill be included 
using different plot symbols. In addition, selected endpoints will be summarised by empirical distribution plots, box plots, and plots of th e mean change from baseline over time. For HbA
1c, 
additional summary tables and plots based on ‚Äòin-trial‚Äô data will also be prepared.
Only endpoints derived after 26 weeks will be analysed statistically. In accordance with guidance18
endpoints will be assessed at frequent visits and also on subjects who discontinue treatment. If an 
assessment has been made both at screening and randomisation, and if not otherwise specified, the 
value from the randomisation visit will be used as the baseline value. If the value measured at the 
randomisation visit is missing and the assessment also has been made at screening, then the screening value will be used as the baseline value.
Laboratory values below the lower limit of quantification (LLOQ) will be set to ¬ΩLLOQ.
Presentation of resu lts from a statist ical analysis w ill include the estimated mean treatment effects 
using least square mean (LSMean) for absolute values, and change from baseline where applicable. The LSMean is either obtained by Rubin‚Äôs rule weighing together LSMeans from multiple 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 50 of 94
imputation estimations or obtained directly  from estimation of a parameterised statist ical model. In 
addition, estimated mean treatment difference (or ratio) will be presented together with the two-
sided 95% confidence interval and corresponding two-sided p-value.
In the statistical models explanatory  fact ors will be coded as follows:
!Treatment: Once weekly insulin 287, Once daily IGlar
!DPP4i has 2 levels (yes and no)
!Region has 2 levels (Europe and North America)
!Visit: Planned visits for actual  endpoint according to flowchart
The impact of protocol deviations and outliers may be investigated further in sensitivity analyses if 
deemed relevant.
10.3.1 Primary endpoint
The primary endpoint is change from baseline to week 26 in HbA 1c.
Primary estimand
For the primary endpoint, the primary estimand is defined as the ‚Äúhypothetical‚Äù est imand19.
The treatment difference between once weekly insulin 287 versus once daily IGlar in change from 
baseline to week 26 in HbA1c for all randomised subjects if all subjects had adhered to treatment 
and did not initiate ancillary treatment in  subjects with T2DM inadequately treated with metformin 
with or without DPP4i.
The primary estimand w ill be es timated based on the FAS. This estimand aims to reflect the 
treatment effect for subjects that are actually able to take the drug during the intended treatment 
period. With the aim of evaluating proof of concept, this estimand is considered releva nt i.e. a de 
jure estimand addressing efficacy.
Subjects may start ancillar y treatment during the trial. Hence, data obtained after occurrence of 
intercurrent event such as initiat ion of ancillary treatment and discontinu ation of randomised 
treatment will not be included in the est imation of the primary estimand.
To estimate this estimand, change from baseline in HbA 1cafter 26 weeks will be analysed with the 
linear mixed model for repeated measurement (MMRM) method with an unstructured covariance matrix. All post baseline HbA
1cmeasurements obtained on planned visits while the subject 
continues the randomised treatment will contribute to the analysis. Hence, data obtained after 
occurrence of the following two intercurrent even ts such as initiation of ancillary treatment and 
discontinuation of randomised treatment will not be included in the estimation of the primary estimand. This analysis has the underlying assumption that the missing data mechanism is ‚Äòmissing 
at random‚Äô. The model will include use of DPP4i (yes/no), region, treatment and visit as fixed 
factors and baseline HbA
1cas covariate. Interactions between visit and all factors and covariates 
will also be included in the model. The estimated mean treatment difference and the confidence 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 51 of 94
interval will be presented together with the c orresponding two-sided p-valu e. In the following, this 
MMRM method will be referred to as the standard MMRM method. 
Secondary estimand
The secondary estimand for the primary en dpoint is the ‚Äútreatment policy‚Äù estimand. 
The secondary estimand is defined as the treatment difference between once weekly insulin 287 
versus once daily IGlar in change from baseline to week 26 in HbA1c for all randomised subjects, 
regardless of the treatment actually received in subjects with T2DM inadequately treated with 
metformin with or without DPP4i. This estimand aims to reflect the treatment effect for all subjects regardless of treatment adherence, i.e. a de facto estimand addressing effectiveness.
This will be estimated using all HbA
1cmeasurements obtained at week 26, also including 
measurements from subjects discontinuing their  randomised treatment or initiating ancillary 
treatment. Missing HbA 1cmeasurements at week 26 will be imputed from trial participants who are 
from the same randomised group, who have discontinued their randomised treatment and have an 
HbA 1c  measurement at week 26.
This will be done as follows:
!First, one thousand (1000) copies of the dataset will be generated.
!Second, for each dataset copy, and each treatmen t group, an analysis of variance (ANOVA) 
model with baseline HbA 1cvalue as a covariate will be fitted to the end of trial value for 
subjects having discontinued their randomised treatment and have an HbA 1cmeasurement at 
week 26. The estimated parameters, and their variances, from the model will be used to 
impute missing values at end of trial in the same treatment group. The factors region and use 
of DPP4i are not consid ered in this step assuming the number of subjects to impute from 
will be low and that may lead the model does not meet the convergence criteria.
!For each of the complete data sets, the change from baseline in HbA 1cafter 26 weeks will be 
analysed using an analysis of co-variance model with use of DPP4i (yes/no), region and 
treatment as fixed factor, and baseline HbA 1cas covariate. The estimates and standard 
deviations for the 1000 data sets will be pooled to one estimate and associated SD using 
Rubin‚Äôs rule.
If less than 3 subjects have discontinued their randomised treatment and have an HbA 1c
measurement at week 26 in any of the treatment groups , then the second step above will be carried 
out combining the two treatment arms and including treatment as factor in the model.
The estimated mean treatment difference and the confidence interval will be presented together with 
the corresponding two-sided p-value.
Sensitivity analysis
The following sensitivity analysis of the assumptions about the missing data will be carried out: for 
the primary estimand, a tipping point like type of analysis will be performed where subjects from 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 52 of 94
the Insulin 287 arm having no HbA1c measurement at week 26 are assumed to have a worse 
outcome compared to what was imputed in the primary analysis. This is done by adding a value Œîi 
to the imputed HbA1c values in the Insulin 287 arm before analysing the data. The resulting estimated treatment differences and 95%CIs will be plotted as function of Œîi to evaluate the 
robustness of the primary analysis results.
10.3.2 Secondary endpoints
10.3.3 Confirmatory secondary endpoints
Not applicable for this trial.
10.3.3.1 Supportive secondary endpoints
The supportive secondary endpoints will be addressed in terms of the frame work of the primary 
estimand only.
Efficacy endpoints
!Change from baseline to week 26 in fasting plasma glucose
!9-point profile (individual SMPG values) at week 26
!Change from baseline to week 26 in mean of the 9-point profile, defined as the area under 
the profile
!Fluctuations of the 9-point profile (defined as the integrated absolute distance from the mean 
profile value divided by measurement time)
!Change from baseline to week 26 in fasting C-peptide
!Change from baseline to week 26 in body weight
!Weekly dose of insulin 287 and daily dose of IGlar at week 26
FPG, C-peptide and body weight ‚Äì change from baseline after 26 weeks
Change from baseline in FPG and body weight will be analysed using the standard MMRM method 
with relevant baseline as the covariate.Relative change from baseline in C-peptide will be analysed using the standard MMRM method. In this statistical analysis the endpoint will be log-transformed and so will the baseline covariate.
SMPG 9-point profile 
The following endpoints will be derived from self-measured plasma glucose,
1. 9-point profile (individual SMPG values)2. Change from bas eline to week 26 in mean of the 9-point profile, defined as the area under 
the profile 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 53 of 94
3. Fluctuations of the 9-point profile defined as the integrated absolute distance from the mean 
profile value divided by measurement time
A linear mixed effect model will be fitted to the 9-point SMPG profile data at week 26. The model 
will include treatment, region, use of DPP4i, time,  the interaction between treatment and time, the 
interaction between region and time, and the interaction between use of DPP4i and time as fixed 
factors and subject as random effect. From the model mean profile by treatment and relevant treatment differences will be estimated and explored.
Change from baseline in mean of the 9-point profile, and fluctuation in 9-point profiles after 26 
weeks will be analysed separately using the standard MMRM method with relevant baseline as the 
covariate. Fluctuation in the 9-point profile will be logarithmically  transformed before analysed.
Baseline fluctuation in the 9-point profile also will be log-transformed in the model.
Insulin dose
Insulin 287 dose and IGlar dose will be summarised by week.The average insulin 287 dose derived from visit 26 to visit 28 versus average weekly IGlar dose 
derived from visit 26 to visit 28 will be logarithmically transformed and analysed based on standard MMRM method (except baseline as a covariate).
Safety endpoints
Number of treatment emergent adverse events from baseline to week 31
AEs will be coded using the most recent version of the Medical Dictionary for Regulatory 
Activities (MeDRA).
The treatment emergent period represents the period where subjects are considered exposed to trial 
product. It starts at the first date of exposure to randomised treatment and ends at the last follow-up visit (FU2), thus includes a time period after last dose of randomised treatment corresponding to 
approximately 5 half-lives of insulin 287. Specifically, it ends at one of the following:
!For subjects completing the tr ial: Last follow-up visit (FU2) 
!For subjects who discontinue: Last follow-up visit (FU2) as defined in section 8.1
!For subjects who discontinue, but do not attend FU2 visit: Last dosing day of randomised 
treatment + 5 weeks for glargine, and last dosing day of randomised treatment + 6 weeks for insulin 287  
A treatment emergent adverse event (TEAE) is defined as an event that has onset date on or after 
the first day of exposure to randomised treatment and no later than the treatment emergent period. If the event has onset date before the first day of exposure on randomised treatment and increases in 
severity during the treatment period and until the treatment emergent period, then this event should 
also be considered as a TEAE.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 54 of 94
TEAEs are summarised descriptively, whereas non-TEAEs are presented in listings. TEAE data 
will be displayed in terms of the number of subjects with at least one event (N), the percentage of 
subjects with at least one event (%), the number of events (E) and the event rate per 100 years of exposure (R).
Summaries of TEAEs and of serious TEAEs will be presented as an overview including all AEs, 
serious AEs, number of deaths, AEs by severi ty, AEs by relation to treatment and AEs of special 
interest including AEs leading to treatment discontinuation or withdrawal.
Furthermore summary tables based on system organ class and preferred terms are made for:
!All TEAEs
!Serious TEAEs
!TEAEs possibly or probably related to trial product
!Severe, moderate and mild TEAEs
!TEAEs reported by safety areas of interest
!TEAEs with preferred term that are experien ced by at least 5% (1%) of the subjects in any 
treatment arm or by at least 5% (1%) of all subjects
A listing for non-TEAEs with onset date before the first day of exposure to randomised treatment 
will be presented. A listing will also be presented for non-TEAEs collected after the treatment-emergent period according to the definition of TEAE.
Additional summaries will be displayed for SAEs, including events collected after premature 
treatment discontinuation (‚Äúin-trial‚Äù summary).
Summary of number of treatment-emergent injection site reactions will be presented as an overview 
including all AEs, serious AEs, AEs by severity a nd AEs by relation to treatment and injection site 
reactions leading to treatment discontinuation or withdrawal. Furthermore summary table of 
injection site reaction based on system organ class and preferred terms will be made.
Hypoglycaemic episodes
For the definition and classification of hypoglycaemic episodes refer to Appendix 8 . Data on 
treatment-emergent hypoglycaemic episodes are presented in terms of the number of subjects with 
at least one episode (N), the percentage of subjects with at least one episode (%), the number of 
episodes (E) and the event rate per 100 years of exposure (R).
Repeated SMPG measurements and/or symptoms (see Table 10-2 ), will by default be considered as 
one hypoglycaemic episode until a succeeding SMPG value is ‚â•3.9 mmol/L (70 mg/dL) and/or 
symptoms have been resolved. The episode s hould be reported as only one hypoglycaemic episode 
on the hypoglycaemic episode CRF. 
In case of several low SMPG values within the hypoglycaemic episode, the lowest value is the one 
that will be reported as the SMPG value for the hypoglycaemic episode but the start time of the 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 55 of 94
episode will remain as the time for the first low SMPG value and/or symptom. The remaining 
values will be kept as source data in the diary. 
Separate summaries will be made according to the level of hypoglycaemia, as recently 
recommended by the International Hypoglycaemia Study Group (2017 joint ADA/EASD position statement), ADA ‚ÄòStandards of Medical Care in Diabetes-2018‚Äô, ISPAD, Type 1 Diabetes 
Outcomes Program and ATTD c ongress. For references see Appendix 8 .
The classification of hypoglycaemia is outlined in Table 10-2 . The summaries are made for all and 
nocturnal (between 00:01 and 05.59 both inclusive) episodes respectively.
Table 10-2 Classification of hypoglycaemia
Level Glycaemic criteria Description
Hypoglycaemia alert value 
(level 1)< 3.9 mmol/L (70 mg/dL) and
‚â• 3.0 mmol/L (54 mg/dL)Sufficiently low for treatment 
with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy
Clinically significant hypoglycaemia (level 2)< 3.0 mmol/L (54 mg/dL) Sufficiently low to indicate 
serious clinically important hypoglycaemia
Severe hypoglycaemia (level 
3)No specific glucose threshold Hypoglycaemia associated 
with severe cognitive 
impairment requiring external assistance for recovery
The treatment emergent period represents the period where subjects are considered exposed to trial product. It starts at the first date of exposure to randomised treatment and ends at the last follow-up visit (FU2), thus includes a time period after last dose of randomised treatment corresponding to approximately 5 half-lives of insulin 287. Sp ecifically, it ends at one of the following:
!For subjects completing the trial: Last follow-up visit (FU2)
!For subjects who discontinue: Last follow-up visit (FU2) as defined in section 8.1
!For subjects who discontinue, but do not attend FU2 visit: Last dosing day of randomised 
treatment + 5 weeks for glargine, and last dosing day of randomised treatment + 6 weeks for 
insulin 287
Level 1 hypoglycaemic episodes, Level 2 and level 3 combined hypoglycaemic episodes, level 2 
hypoglycaemic episodes, and level 3 hypoglycaemic episodes after 26 weeks will be analysed 
separately by a negative binomial regression model with treatment, region and use of DPP4i 
(yes/no) as fixed factors and the log of time period (treatment-emergent) for which the hypoglycaemic episodes are considered as an offset.
The above analysis will be repeated for the following time points as below,
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 56 of 94
1. Number of level 2 and level 3 combined hypoglycaemic episodes from baseline to week 31 
(Treatment emergent hypos)
2. Number of level 2 and level 3 combined hypoglycaemic episodes from baseline to week 16 
(Titration period)
3. Number of level 2  and level 3 combined hypoglycaemic episodes from week 17 to week  26 
(Maintenance period)
4. Number of level 2 hypoglycaemic episodes from baseline to week 31 (Treatment emergent 
hypos)
5. Number of level 2 hypoglycaemic episodes from baseline to week 16 (Titration period)
6. Number of level 2 hypoglycaemic episodes from week 17 to week  26 (Maintenance period)
7. Number of level 3 hypoglycaemic episodes from baseline to week 31 (Treatment emergent 
hypos)
8. Number of level 3 hypoglycaemic episodes from baseline to week 16 (Titration period)
9. Number of level 3 hypoglycaemic episodes from week 17 to week  26 (Maintenance period)
The number of nocturnal level 2 and level 3 combined hypoglycaemic episodes and number of level 
2 hypoglycaemic episodes, and number of level 3 hypoglycaemic episodes from:
!baseline to 26 weeks
!baseline to week 31
!baseline to week 16 and
!week 17 to week 26
will be analysed similarly.
Antibodies from baseline to 31 weeks
Change in anti-insulin 287 antibodies level, and cha nge in anti-insulin 287 antibody titres will be 
summarised and tabulated. The correlation between change in values from baseline after 31 weeks 
of treatment in anti-insulin 287 antibodies level, and anti-insulin 287 antibody titres respectively to insulin dose at 26 weeks of treatment, HbA1c after 26 weeks of treatment and change from baseline after 26 weeks of treatment in HbA1c will be illustrated using scatter plots. The Pearson‚Äôs 
correlation coefficient will be tested and disp layed in both table and the plots. Number and 
percentage of subjects positive for cross r eactive antibodies will be tabulated by visit.
10.3.3.2 Exploratory endpoints
!Insulin 287 concentrations, evaluated in a population PK analysis
!Time in target-ra nge 3.9-7.8 mmo l/L (70‚Äì140 mg/dL) measured by flash glucose monitoring 
(FGM) (  Free Style Libre Pro) during the last 2 weeks of treatment (week 25 and 26)
The data accuracy may vary during the first 24 hours after sensor fitting, the FGM data from the 1st 
day (24h) of each sensor period will be excluded from analysis.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 57 of 94
10.3.7 Other analyses
Other efficacy tabulations:
HbA 1cresponders after 26 weeks (Yes/No)
Dichotomous outcome (responder=yes/non-responder=no) will be defined based on whether a 
subject has met a specific level of HbA 1c< 7.0% after 26 weeks. Analysis of this responder 
outcome will be based on a logistic regression mo del with treatment, re gion and use of DPP4i as 
fixed factors and baseline HbA 1c values as covariate.
For subjects who discontinue randomised treatment or start ancillary treatment, missing HbA 1cdata 
at 26 weeks are imputed by the MMRM method before applying the specific responder criteria.
HbA 1cresponders with minimal weight gain after 26 weeks
Responder for HbA 1cwith minimal weight gain after 26 weeks of treatment will be defined as:
!HbA 1c< 7.0% and change from baseline in body weight ‚â§ 3 %
Analysis of this responder outcome will be based on a logistic regression model with treatment, 
region and use of DPP4i as fixed factors and baseline HbA 1cand baseline body weight values as 
covariates.
For subjects who discontinue randomised treatment or start ancillary treatment, missing HbA 1cand 
body weight data at 26 weeks are imputed by the MMRM method before applying the specific responder criteria.
HbA
1cresponders without treatment-emergent clinically significant hypoglycaemic episodes 
and without treatment-emergent severe hypoglycaemic episodes after 26 weeks
Responder for HbA 1cwithout treatment-emergent clinically significant hypoglycaemic episodes and 
without treatment-emergent severe hypoglycaemic episodes after 26 weeks of treatment will be defined as:
!HbA
1c< 7.0% and without treatment-emergent clinically significant hy pogly caemic 
episodes and without treatment-emergent severe hypoglycaemic episodes during the last 12 
weeks of treatment
Analysis of this outcome will be based on a logistic regression model with treatment, region and use 
of DPP4i as fi xed factors and baseline HbA 1cvalues as covariates, where subjects with less than 12 
weeks of treatment conservatively will be set to being non-responder.
For subjects who discontinue randomised treatment or start ancillary treatment, missing HbA 1cdata 
at 26 weeks are imputed based on the MMRM method before applying the specific responder criteria.
HbA
1cresponders without treatment-emergent severe hypoglycaemic episodes after 26 weeks
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 58 of 94
Responder for HbA 1cwithout treatment-emergent severe hypoglycaemic episodes after 26 weeks of 
treatment will be defined as:
!HbA 1c< 7.0% and without treatment-emergent severe hypoglycaemic episodes during the 
last 12 weeks of treatment
Analysis of this endpoint will be based on a l ogistic regression model with treatment, region and 
use of DPP4i as fixed factors and baseline HbA 1cvalues as covariates, where subjects with less than 
12 weeks of treatment conservatively will be set to being non-responder.
For subjects who discontinue randomised treatment or start ancillary treatment, missing HbA 1cdata 
at 26 weeks are imputed based on the MMRM method before applying the specific responder criteria.
HbA
1cresponders without treatment-emergent clinically significant hypoglycaemic episodes 
and with minimal weight gain after 26 weeks
Responder for HbA 1cwithout treatment-emergent clinically significant hypoglycaemic episodes and 
with minimal weight gain after 26 weeks of treatment will be defined as:
!HbA 1c< 7.0% without treatment-emergent clin ically significant hypoglycaemic episodes 
during the last 12 weeks of treatment, and change from baseline in body weight ‚â§3 %
Analysis of this responder outcome will be based on a logistic regression model with treatment, 
region and use of DPP4i as fixed factors and baseline HbA 1cand body weight values as covariates, 
where subjects with less than 12 weeks of treatment will conservatively be set to being non-responder.
For subjects who discontinue randomised treatment or start ancillary treatment, missing HbA
1cand 
body weight data at 26 weeks are imputed by the MMRM method before applying the specific 
responder criteria.
HbA 1cresponders without treatment-emergent severe hypoglycaemic episodes and with 
minimal weight gain after 26 weeks
Responder for HbA 1cwithout treatment-emergent severe hypoglycaemic episodes and with minimal 
weight gain after 26 weeks of treatment will be defined as:
!HbA 1c< 7.0% without treatment-emergent severe hypoglycaemic episodes during the last 
12 weeks of treatment, and change from baseline in body weight ‚â§3 %
Analysis of this responder outcome will be based on a logistic regression model with treatment, 
region and use of DPP4i as fixed factors and baseline HbA 1cand body weight values as covariates, 
where subjects with less than 12 weeks of treatment will conservatively be set to being non-responder.
For subjects who discontinue randomised treatment or start ancillary treatment, missing HbA
1cand 
body weight data at 26 weeks are imputed by the MMRM method before applying the specific 
responder criteria.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 59 of 94
Similar analyses as defined above will be carried out for responder targets replacing HbA 1c<7.0% 
with HbA 1c‚â§6.5%.
FPG responder to treatment target after 26 weeks (Yes/No)
Dichotomous outcome (responder=yes/non-responder=no) will be defined based on whether a 
subject has met a specific target level of FPG ‚â§ 7.2 mmol/L (130 mg/dL) after 26 weeks. Analysis 
of this responder endpoint will be based on a logistic regression model with treatment, region and 
use of DPP4i as fixed factors and baseline FPG values as covariate.
For subjects who discontinue randomised treatment or start ancillary treatment, missing FPG data at 
26 weeks are imputed by the MMRM method before applying the specific responder criteria.
Similar analyses as defined above will be carr ied out for responder targ ets replaci ng <7.2 mmol/L 
(130 mg/dL) with ‚â§ 6 mmol/L (108 mg/dL).
Other safety tabulations:
Antibodies from baseline to 31 weeksNumber and percentage of subjects positive for anti-insulin 287 and anti-insulin glargine antibodies 
will be tabulated by visit. Anti-insulin glargine antibodies (both in %B/T and titres) will be summarised and tabulated. The correlation between change in titre values from baseline after 26 weeks of treatment in anti-insulin glargine, to insulin dose after 26 weeks of treatment, HbA1c after 
26 weeks of treatment and change from baseline after 26 weeks of treatment in HbA1c will be 
illustrated using scatter plots. Also the Pearson' s correlation coefficient will be tested and displayed 
in both table and the plots.
Clinical evaluation (ECG, eye examination and physical examination) change from baseline 
after 26 weeks
Eye examination (fundoscopy/fundus photography) a nd 12-lead ECG findings will be summarised 
descriptively, including:
!Summaries for each visit
!Shift tables from baseline to after 26 weeks
Laboratory assessment (Biochemistry and Haematology) - change from baseline after 26 
weeksAll laboratory parameters will be summarised descriptively including:
!Summaries by visit
!Shift tables from baseline to after 26 weeks
!Proportion of subjects with measurements outsi de reference range by treatmen t and week
!Box plots by time since randomisation
!Listings of individual values outside reference ranges (abnormal values)
Lipids and vital signs
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 60 of 94
Lipids and vital signs will be summarised by treatment.
Other exploratory tabulations:
Time in target-range measured by FGM, Libre Pro will be analysed using the standard MMRM 
method except baseline as a covariate for the following time in range,
!Time in range 3.9‚Äì6.0 mmol/L (70 -108 mg/dL)
!Time in range 3.9‚Äì10.0 mmol/L (70- 180 mg/dL)
!Time spent < 3.0 mmol/L (54 mg/dL)
!Time spent < 3.9 mmol/L (70 mg/dL)
!Time spent > 10.0 mmo l/L (180 mg/dL)
!Time spent > 13.9 mmol/L (250 mg/dL)
Within subject variability as measured by CV%
The logarithm transformed FGM values will be analysed as repeated measures in a linear mixed 
model with treatment, us e of DPP4i and region as fixed factors and subject as random factor. The 
model will assume independent within- and between-subject errors with variances depending on treatment. Within subject variability as measur ed by CV% for a treatment can be calculated from 
the corresponding residual variance ‚àÄ
2as %= (   (  )‚àí1). The confidence interval for the 
CV ratio between treatments will be calculated using the delta method.
For population PK analysis refer section 10.4.
10.4 Pharmacokinetic and/or pharmacodynamic modelling
Insulin 287 serum concentration data will be used for a population PK analysis. The objective of the 
population PK analysis is to evalu ate the effects of pre-specified covariates on serum concentrations 
of insulin 287.
The population PK analysis will be performed by Quantitative Clin ical Pharmacology, Novo 
Nordisk A/S. A more technical a nd detailed elaboration of the population PK analysis will be given 
in a modelling analysis plan (MAP), which will be prepared before Database Lock (DBL). In brief, 
a previously developed PK model for insulin 287 will be applied. The absorption rate constant (Ka) 
in the model will be fixed, and the apparent clearance (CL/F) and the apparent volume of distribution (V/F) will be re-estimated. The covariates of interest will be incorporated into the PK model using criteria which will be specified in the MAP.
The population PK analysis will be reported in a separate modelling report, which will not be a part 
of the clinical trial report. The individual insulin 287 serum concentration data will be tabulated in the bioanalytical report (BAR).
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 61 of 94
11 References
1. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly 
medications for diabetes. Diabetes Obesit y & Metabolism. 2011;13(2):144 -9.
2. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). 
Guideline on clinical investigation of medicinal products in the treatment or prevention of 
diabetes mellitus (CPMP/EWP/1080/00 Rev. 1). Adoption by CHMP. 14 May 2012.
3. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Diabetes Mellitus: Developing Drugs  and Therapeutic Biologics for Treatment 
and Prevention, Draft Guidance. February 2008.
4. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in 
Diabetes-2018. Diabetes Ca re. 2018;41(Suppl 1):S55-S64.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of complications 
in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53, Erratum 
1999; 354: 602.
6. American Diabetes Association. Abridged for Primary Care Providers. Clin Diabetes. 
2018;36(1):14-37.
7. Novo Nordisk A/S. Investigator's Brochure, NNC0148-0287 (insulin 287), NN1436, 
(edition 4). 2016.
8. Sanofi-Aventis Groupe. Lantus¬Æ   (insulin glargine), EU Summary of Product 
Characteristics (SmPC). 01 Mar 2017.
9. Food and Drug Administration. Lantus - U.S. Label information. 2015.
10. Local SmPC for metformin, current version. 2008 2008.
11. American Diabetes Association. 8. Pharm acologic Approaches to Glyce mic Treatment: 
Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73-S85.
12. Hauber AB, Johnson FR, Sauriol L, Lescrau waet B. Risking health to avoid injections: 
preferences of Canadians with type 2 diabetes. Diabetes Care. 2005;28(9):2243-5.
13. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). 
Module V ‚Äì Risk management systems (Rev 1) (EMA/838713/2011 Rev 1). 15 Apr 2014.
14. the European Economic Community. Me dical Device Directive 93/42, Annex I. 1993.
15. U.S. Department of Health and Human Services, Food and Drug Administration, Center for 
Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance 
for Industry. Bioanalytical Method Validation. 2001.
16. European Medicines Agency (EMA) Cf MPfHUC. Guideline on Bioanalytical Method 
Validation. EMEA/CHMP/19221/2009. 21 July 2011. 7/21/2011 2011.
17. Little RJA, Rubin DB. Statistical analysis with missing data: New York: John Wiley & 
Sons. 1987.
18. National Academy of Sciences (NAS). The Prevention and Treatment of Missing Data in 
Clinical Trials. Washington D.C.: The National Academies Press. 2010.
19. Mallinckrodt CH, Lin Q, Lipkovich I, Molenberghs G. A structured approach to choosing 
estimands and estimators in longitudinal clinical trials. Pharm Stat. 2012;11(6):456-61.
20. World Medical Association. Declaration of Helsinki - Ethical Principles for Medical 
Research Involving Human Subjects. Last amended by the 64th WMA General Assembly, 
Fortaleza, Brazil. 1 Oct 2013.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 62 of 94
21. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R2), Current 
Step 4 version. 09 Nov 2016.
22. International Organization for Standardization. ISO 14155:2011, Clinical investigation of 
medical devices for human subjects - Good clinical practice. 01 Feb 2011.
23. Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Stockbridge NL, et al. 
Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials 
(Draft). 20 Aug 2014.
24. International Committee of Medicinal Journa l Editors. Uniform Requirements for 
Manuscripts submitted to Biomedical Journals.: N Engl J Med; 1997 1997. p. 309-15.
25. International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
available at www.icmje.org.
26. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1.
27. U.S. Food and Drug Administration. Food and Drug Administration Amendments Act of 
2007 as amended by the Final Rule "Clinical Trials Registration and Results Information 
Submission". 21 September 2016.
28. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of 4 April 2001 on the approximation of the 
laws, regulations and administrative provisions of the Member States relating to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal 
products for human use, article 11. Official Journal of the European Communities. 01 May 
2001.
29. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation  and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 30 
April 2004.
30. International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 
mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of 
the American Diabetes Association and the European Association for the Study of Diabetes. 
Diabetes Care. 2017;40(1):155-7.
31. Jones TW, Group IHGW. Defining relevant hypoglycemia measures in children and 
adolescents with type 1 diabetes. Pediatr Diabetes. 2017.
32. Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, et al. 
Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 
Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, 
the American Association of Diabetes Educators, the American Diabetes Association, the 
Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable 
Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 
2017;40(12):1622-30.
33. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International 
Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-40.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 63 of 94
34. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
35. U.S. Department of Health and Human Services FaDA, ; Center for Drug Evaluation and 
Research (CDER),; Center for Biologics Evaluation and Research (CBER),; Center for 
Devices and Radiological Health (CDRH ),. Guidance for Industry. Patient-Reported 
Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 
2009.
36. Stull DE, Leidy NK, Parasuraman B, Chassa ny O. Optimal recall periods for patient-
reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-
42.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 64 of 94
12 Appendices
Abbreviations and Trademarks Appendix 1
ADA American Diabetes Association
AE adverse event
ALT alanine aminotransferas e
AST aspartat eaminotransferase
BG blood glucose
BMI body mass index
CRF case report form
CTR clinical trial report
DFU directions for use
DPP-4i dipeptidyl peptidase-4 inhibitor
DRE disease related event
DUN dispensing unit number
EAC event adjudication committee
EAS event adjudication system
ECG Electrocardiogram
eCRF electronic case report form
eGFR estimated Glomerular Filtration Rate
EMA European Medicines Agenc y
FAS full analysis set
FDA U.S. Food and Drug Administration
FDAAA FDA Amendments Act
FGM flash glucose monitoring
FPG fasting plasma glucose
FSH follicle-stimulating hormone 
GCP Good Clinical Practice
HbA 1c glycated haemoglobin
ICH International Council for Harmonisation
IEC independent ethics committee
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 65 of 94
IGlar insulin glargin e
IMP investigational medicinal product
IRB institutional review board
ITT Intention to treat
IUD intrauterine device
IUS intrauterine hormone-releasing system 
IWRS interactive web response system
LDL lo w-density lipoprotein
MACE major adverse cardiovascular event
NIMP Non-investigational medical product
OAD oral antidiabetic drug 
PCD primary completion date
PD pharmacodynamic
PG plasma glucose
PK pharmacokinetic
SAE serious adverse event
SD standard deviation
SMPG sel f-measured plasma glucose
SUSA R suspected unexpected serious adverse reaction
T¬Ω hal f- life
T2DM type 2 diabetes mellitus
TEAE treatment emergent adverse event
TMM trial materials manual
ULN upper limit of normal
WOCBP woman of child bearing potential
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 66 of 94
Clinical laboratory tests Appendix 2
!The tests detailed in Table 12-1 and Table 12-2 will be pe rformed by the central laboratory, 
unless otherwise specified.
!Additional tests may be performed at any time during the trial as determined necessary by 
the investigator or required by local regulations. Only laboratory samples specified in the 
protocol should be sent to the central laboratory for analysis; if addit ional laboratory sampling is needed, e.g. to follow up on AEs, this must be done at a local laboratory.
!The investigator must review all laboratory results for concomitant illnesses and AEs.
!Laboratory samples will be destroyed on an ongoing basis and no later than at finalisation of 
the clinical trial report. 
!PK samples will be destroyed at finalisation of the clinical trial report. 
!Antibody sample s and samples to assess systemic hypersensitivity reactions will be stored as 
described in Appendix 7 .
Table 12-1 Protocol-required efficacy laboratory assessments
Laborator y assessments Parameters
Glucose metabolism !FPG (Fasting plasma glucose)
!HbA 1c
!Fasting C-peptide
NOTES :
1 A FPG result < 3.9 mmol/L (70 mg/dL) in relation to planned fasting visits should not be reported as a hypoglycaemic 
episode but as an adverse event at the discretion of the investigator ( Appendix 4 ).
Table 12-2 Protocol-required safety laboratory assessments
Laborator y assessments Parameters
Haematolog y !Erythrocytes
!Haematocrit
!Haemoglobin
!Leucocytes
!Thrombocytes
!Differential count (eosinophils, neutrophils, basophils, monocytes and 
lymphocytes) 
Biochemistr y1!Alanine Aminotransferase (ALT) 
!Albumin
!Alkaline phosphatase
!Aspartate Aminotransferase (AST)
!Creatinine
!Potassium
!Sodium
!Bilirubin
Lipids !Cholesterol
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 67 of 94
!High density lipoprotein (HDL) cholesterol
!Low density lipoprotein (LDL) cholesterol
!Triglycerides
!Free fatty acid
Pregnanc yTesting !Serum or urine human chorionic gonadotropin (hCG) pregnancy test (for women 
of childbearing potential)
Other tests !eGFR calculated by the central laboratory based on the creatinine value using the 
CKD-EPI equation
!Anti-insulin 287 antibodies
!Anti-insulin glargine antibodies
!Pharmacokinetics
!Additional blood samples in case of a systemic hypersensitivity reaction:
oTryptase 
oTotal IgE
oAnti-NNC0148-0287 IgE antibodies  
oAnti-NNC0148-0287 binding antibodies
oHistamine release (basophil) assay 
oAnti-human insulin IgE antibodies
Notes :
1Details of required actions for increased liver parameters  are given in Appendix 4 (Hy‚Äôs Law)
Trial-required laboratory assessments will be performed by a central laboratory, with the exception 
of: 
!Urine pregnancy tests which are performed locally
!Anti-insulin 287 antibodies, anti-insulin glargine antibodies, pharmacokinetics and 
additional blood samples  in case of a systemic hypersensitivity r eaction which are 
performed at special lab.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 68 of 94
Trial governance considerations Appendix 3
1) Regulatory and ethical considerations
!This trial will be conducted in accordance with the protocol and with the following:
!Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki20, applicable ICH Good Clinical Practice (GCP) Guideline21and
ISO 1415522
!Applicable laws and regulations
!The protocol, informed consent form, investigator‚Äôs brochure (as applicable) and other 
relevant documents (e.g. advertisements), must be submitted to an IRB/IEC and reviewed 
and approved by the IRB/IEC before the trial is initiated.
!Regulatory authorities will receive the clin ical trial application, protocol amendments, 
reports on SAEs, and the clinical trial report according to national requirements.
!Any amendments to the protocol will require  IRB/IEC approval be fore implementation of 
changes made to the trial design, except for changes necessary to eliminate an immediate 
safety hazard to trial subjects.
!Before a trial site is allowed to start screening subjects, written notification from Novo 
Nordisk must be received.
!The investigator will be responsible for:
oproviding written su mmaries of the status of the trial a nnually or more frequently in 
accordance with the requirements, policies, and procedures established by the IRB/IEC and/or regulatory authorities
onotifying the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures
oproviding ove rsight of the conduct of the trial at the site and adherence to 
requirements of  ICH guidelines, the IRB/IEC, and all other applicable local regulations
oensuring submission of the clinical trial report (CTR) synopsis to the IRB/IEC.
2) Financial disclosure
Investigators and subinvestigators will provide Novo Nordisk with sufficient, accurate financial 
information as requested to allow Novo Nordisk to submit complete and accurate financial 
certification or disclosure statements to the appropr iate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the trial and one year after completion of the trial.
For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 69 of 94
3) Informed consent process
!The investigator or his/her representative will explain the nature of the trial to the subject 
and answer all questions regarding the trial.
!The investigator must inform the subject about the long-term storage of additional blood 
samples e.g. for exploratory investigation of antibodies or further development of anti-
insulin antibody assays or to assess systemic hype rsensitivity reactions . The subject must be 
informed that he/she is free to refuse to participate and may withdraw consent to the long term storage of the additional blood samples any time and for any reason during the storage 
period.
!The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial. 
!Subjects must be informed that their participation is voluntary.
!Subjects will be required to sign and date a statement of informed consent that meets the 
requirements of local regulations, ICH guidelines
21, Declaration of Helsinki20and the 
IRB/IEC or trial site.
!The medical record must include a statemen t that written informed consent was obtained 
before any trial related activity and the date when the written consent was obtained. The 
authorised person obtaining the informed consent must also sign and date the informed consent form before any trial related activity.
!The responsibility of seeking informed consent must remain with the investigator, but the 
investigator may delegate the task of informing to a medically qualified person, in 
accordance with local requirements.
!Subjects must be re-consented to the most current version of the informed consent form(s) 
during their participation in the trial.
!A copy of the informed consent form(s) must be provided to the subject.
4) Information to subjects during trial
The site will be offered a communication package for the subject during the conduct of the trial. 
The package content is issued by Novo Nordisk. The communication package will contain written 
information intended for distribution to the subjects. The written information will be translated and adjusted to local requirements and distributed to and reviewed with the subject at the discretion of the investigator. The subject may receive a ‚Äúwelcome to  the trial letter‚Äù a nd a ‚Äúthank y ou for your 
participation letter‚Äù after completion of the trial. Further the subject may receive other written 
information during the trial. 
All written information to subjects must be sent to IRB/IEC for approval/favourable opinion and to 
regulatory authorities for a pproval or notification according to local regulations.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 70 of 94
5) Data protection
!Subjects will be assigned a 6-digit unique identifier, a subject number which will remain the 
same throughout the trial. Each site is assigned a 3-digit number and all subject numbers 
will start with the site number. Any subject records or datasets that are transferred to Novo Nordisk will contai n the identifier only; subject names or any information which would 
make the subject identifiable will not be transferred.
!The subject and any biological m aterial obtained from the sub ject will be identified by 
subject number, visit number and trial ID. Appropriate measures such as encryption or 
leaving out certain identifiers will be enforced to protect the identity of subjects as required 
by local, regional and national requirements.
!The subject must be informed that his/her personal trial related data will be used by Novo 
Nordisk in accordance with local data protection law. The disclosure of the data must also 
be explained to the subject. 
!The subject must be informed that his/her medical records may be examined by auditors or 
other authorised personnel appointed by N ovo Nordisk, by appropriate IRB/IEC members, 
and by inspectors from regulatory authorities.
6) Committee structure
Novo Nordisk safety committee
Novo Nordisk will constitute an internal insulin 287 safety committee to perform ongoing safety 
surveillance. The Insulin 287 safety co mmittee ma y reco mmend unblinding of any data for further 
analysis, and in this case an independent ad hoc group will be established in order to maintain the 
blinding of the trial personnel.
Event adjudication committee
An independent external EAC is established to perform ongoing blinded adjudication of selected 
AEs and death (see Table 9-1 and Appendix 4 ). The EAC will evaluate events sent for adjudication 
using pre-defined definitions and guidelines in accordance with the EAC Charter. The evaluation is 
based on review of pre-defined clinical data collected by the investigational sites. 
The EAC is composed of permanent members covering all required medical specialities. EAC 
members must disclose any potential conflicts of interest and must be independent of Novo Nordisk. The EAC w ill have no authority to impact on trial conduct, trial protocol or amendments.
Hypersensitivity reactions were observed with previous Formulation A, which was subsequently 
optimised to the current Formulation C. No hypersensitivity reactions have so far been observed with Formulation C. However, event adjudication for hypersens itivity reactions (local reactions, 
including injection site reactions and systemic reactions , including anaphylaxis) is introduced in the 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 71 of 94
present trial to ensure standardised and objective assessment by an independent adjudication 
committee of experts within the specialty.
The cardiovascular events will be adjudicated in accordance with FDA requirements23. 
The AEs for adjudication are listed in Table 9-1 and Appendix 4 .
Global expert panel
A global expert panel will consist of investigators pa rticipating in the trial in different countries and 
of designated Novo Nordisk employees. The pa nel will discuss and advice on global and local 
operational issues related to trial conduct.
7) Publication policy
The information obtained during the conduct of this trial is considered confidential, and may be 
used by or on behalf of Novo Nordisk for regulatory purposes as well as for the general development of the trial product. All information supplied by Novo Nordisk in connection with this trial shall remain the sole property of Novo Nordis k and is to be considered confidential 
information.
No confidential information shall be disclosed to others without prior written consent from Novo 
Nordisk. Such infor mation shall not be used except in the performance of this trial.
The information obtained during this trial may be made available to other investigators who are 
conducting other clinical trials with the trial produ ct, if deemed necessary by Novo Nordisk. 
Provided that certain conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to researchers who require access for research projects studying the same disease and/or trial product studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
One investigator will be appointed by Novo Nordisk to review and sign the clinical trial report (signatory investigator) on behalf of all participating investigators. The signatory investigator will be appointed based upon the criteria defined by the International Co mmit tee of Med ical Journal 
Editors for research publications
24.
Communication of results
Novo Nordisk commits to communicate and disclose results of trials regardless of outcome. 
Disclosure includes publication of a manuscript in a peer-reviewed scientific journal, abstract 
submission with a poster or oral presentation at a scientific meeting or disclosure by other means. 
The results of this trial will be subject to public disclosure on external web sites according to 
international and national regulations. Novo Nordi sk reserves the right to defer the release of data 
until specified milestones are reached, for example when the clinical trial report is available. This 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 72 of 94
includes the right not to release the results of interim analyses, because the release of such 
information may influence the results of the entire trial.
At the end of the trial, one or more scientif ic publications may be prepared collaboratively by the 
investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. In the event of any disagreement on the content of any publication, both the investigators‚Äô and Novo Nordisk opinions will be fairly and sufficiently represented in the publication.
Authorship
Novo Nordisk will work with one or more investigator(s) and other experts who have contributed to 
the trial concept or design, acquisition, analysis or interpretation of data to report the results in one or more publications.
Authorship of publications should be in accordance with the Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals by the International Committee of Medical Journal Editors
25.
All authors will be provided with the relevant statistical tables, figures, and reports needed to 
evaluate the planned publication. 
Where required by the journal, the investigator from each trial site will be named in an 
acknowledgement or in the s upplementary m aterial, as specified by the journal. 
Site-specific publication(s) by investigator(s)
For a multicentre clinical trial, analyses based on single-site data usually have significant statistical limitations and frequently do not provide meaningful information for h ealthcare professionals or 
subjects, and therefore may not be supported by Novo Nordisk. Thus, Novo Nordisk may deny a request or ask for deferment of the publication of individual site results until the primary manuscript 
is accepted for publication. In line with Good Publication Practice, such individual reports should 
not precede the primary manuscript and should always reference the primary manuscript of the trial.
Investigator access to data and review of results
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database.
Individual investigators will have their own research subjects' data, and will be provided with the 
randomisation code after results are available.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 73 of 94
8) Dissemination of clinical trial data
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk-trials.com. It will also 
be disclosed according to other applicable requirements such as those of the International Committee of Medical Journal Editors (ICMJE)
26, the Food and Drug Administration Amendment 
Act (FDAAA)27, European Commission Requirements(28, 29, )and other relevant recommendations 
or regulations. If a subject requests to be included in the trial via the Novo Nordisk e-mail contact at 
these web sites, Novo Nordisk may disclose the investigator‚Äôs contact details to the subject. As a result of increasing requirements for transparency, some countries require public disclosure of investigator names and their affiliations.
The Primary Completion Date (PCD) is the last assessment of the primary endpoint, and is for this 
trial Last Subject First Treatm ent (LSFT) + 26 weeks corresp onding to Visit 28. If the last subject is 
withdrawn early, the PCD is considered the date when the last subject randomised in the trial would have completed end of treatment Visit 28. The PCD determines the deadline for results disclosure at 
clinicaltrials.gov according to FDAAA.
9) Data quality assurance
Case Report Forms (CRFs)
!Novo Nordisk or designee is responsible for the data management of this trial including 
quality checki ng of the data.
!All subject data relating to the trial will be recorded on electronic CRFs unless transmitted 
electronically to Novo Nordisk or designee (e.g. laboratory and FGM Libre Pro data). The 
investigator is responsible for verifying that data entries are accurate and correct by 
physically or electronically signing the eCRF. 
!The following will be provided as paper CRFs:
oPregnancy forms
!The following will be provided as paper CRFs to be used when access to the CRF is revoked 
or the CRF is temporarily unavailable:
oAE forms 
oSafety information forms 
oTechnical complaint forms (also to be used to report complaints that are not subject 
related, e.g. discovered at trial site before allocation)
!Corrections to the CRF data may be made by the investigator or the investigator‚Äôs delegated 
staff. An audit trail will be maintained in the CRF application containing as a minimum: the 
old and the new data, identif ication of the person entering the data, d ate and time of the 
entry and reason for the correction. If corrections are made by the investigator‚Äôs delegated 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 74 of 94
staff after the date when the investigator signed the CRF, the CRF must be signed and dated 
again by the investigator.
!The investigator must ensure that data is recorded in the CRF as soon as possible, preferably 
within 5 working days after the visit. Once data has been entered, it will be available to 
Novo Nordisk for data verification and validation purposes.
Monitoring
!The investigator must per mit trial-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents (original 
documents, data and records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are important to the evaluation of the trial. If the electronic medical record does not have a visible audit trail, the investigator must 
provide the monitor with signed and dated printouts. In addition the relevant trial site staff 
should be available for discussions at monitoring visits and between monitoring visits (e.g. by telephone). 
!Trial monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by authorised site personnel ar e accurate, complete and verifiable from source 
documents; that the safety and rights of subjects are being protected, to monitor drug 
accountability and collect completed paper CRF pages, if applicable, and that the trial is 
being conducted in accordance with the currently approved protocol and any other trial agreements, ICH GCP, and all applicable regulatory requirements.
!Monitoring will be conducted using a risk based approach including risk assessment, 
monitoring plans, centralised monitoring (remote assessment of data by Novo Nordisk) and 
visits to trial sites. 
!Monitors will review the subject‚Äôs medical records and other source data e.g. the diaries to 
ensure consistency and/or identify omissions compared to the CRF. 
Protocol compliance
Deviations from the protocol should be avoided. If deviations do occur, the investigator mu st 
inform the monitor and the implications of the deviation must be reviewed and discussed.
Deviations must be documented and explained in a protocol deviation by stating the reason, date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the CRF or via listings from the trial database. 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 75 of 94
10) Source documents
All data entered in the CRF must be verifiable in source documentation other than the CRF.
!The original of the completed diaries must not be removed from the trial site.
!Source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data collected. Source documents are filed at the trial site.
!Data reported on paper CRF or entered in the electronic CRF that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must 
be explained. The investigator may need to request previous medical records or transfer records. Also, current medical records must be available. 
!
It must be possible to verify subject‚Äôs medical  history in source documents such as subject‚Äôs 
medical record.
!The investigator must document any attempt to obtain external medical information by 
noting the date(s) when information was requested and who was contacted.
!Definition of what constitutes source data can be found in a source document agreement at 
each trial site. There will only be one source document defined at any time for any data 
element.
11) Retention of clinical trial documentation
!Records and documents, including signed informed consent forms, pertaining to the conduct 
of this trial must be retained by the investigator for 15 years after end of trial unless local 
regulations or institutional policies require a longer retention perio d. No records may be 
destroyed during the retention period without the written approval of Novo Nordisk. No 
records may be transferred to another location or party without written notification to Novo 
Nordisk. 
!The investigator must be able to access his/ her trial documents without involving Novo 
Nordisk in any way. If applicable, electronic CRF and other subject data will be provided in 
an electronic readable format to the investigator before access is revoked to the systems 
and/or electronic devices supplied by Novo Nordisk. Site-specific CRFs and other subject 
data (in an electronic readable format or as paper copies or prints) must be retained by the trial site. If the provided electronic data (e.g. the CD -ROM) is not readable during the entire storage period, the investigator can request a new copy. A copy of all data will be stored by 
Novo Nordisk.
!Subject‚Äôs medical records must be kept for the maximum period permitted by the hospital, 
institution or private practice
12) Trial and site closure
Novo Nordisk reserves the right to close the trial site or terminate the trial at any time for any 
reason at the sole discretion of Novo Nordisk. If the trial is suspended or terminated, the 
investigator must inform the subjects promptly and ensure appropriate therapy and follow-up. The 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 76 of 94
investigator and/or Novo Nordisk must also promptly inform the regulatory authorities and 
IRBs/IECs and provide a detailed written explanation.
Trial sites will be closed upon trial completion. A tr ial site is considered closed when all required 
documents and trial supplies have been collected and a trial site closure visit has been performed.
The investigator may initiate trial site closure at  any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a trial site by Novo Nordisk or investigator may include but are not limited to:
!failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, Novo Nordisk procedures or GCP guidelines
!inadequate recruitment of subjects by the investigator
!discontinuation of further trial product development.
13) Responsibilities
The investigator is accountable for the conduct of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-related duties. The investigator must ensure th at there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator‚Äôs responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the subjects. 
A qualified physician, who is an investigator or a subinvestigator for the trial, must be responsible for all trial-related  medical decisions. 
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents, including the subject identification code list must be kept in a secure locked fac ility so that no unauthorized persons can get access to 
the data. 
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any unauthorised access to data or any other processing of data against applicable law. The investigator must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires) a 
new investigator will be appointed in  consultation with Novo Nordisk. 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 77 of 94
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).
14) Indemnity statement 
Novo Nordisk carries product liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials  in any country, unle ss others have shown 
negligence. 
Novo Nordisk assumes no liability in the event of ne gligence or any other liability of the sites or 
investigators conducting the trial or by persons  for whom the said site or investigator are 
responsible. 
Novo Nordisk accepts liability in accordance with: 
!The Civil Code and the Pharmaceutical Law dated 6 September 2001 (uniform version 
Journal of Laws of 2008 No.45 item 271 with amendments) for Poland, please see Appendix
10for details.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 78 of 94
Adverse events: definitions and procedures for Appendix 4
recording, evaluation, follow-up, and reporting
AE definition
!An AE is any untoward medical occurrence in a clinical trial subject administered or using a medicinal 
product, whether or not considered related to the medicinal product or usage. 
!An AE can be any unfavourable and unintended sign, including an abnormal laboratory finding, symptom or 
disease (new or exacerbated) temporally associated with the use of a medicinal product. Note 1: This includes events related to the procedures involved (any procedure in the protocol).
Note 2: For users or other persons this is restricted to events related to the investigational medical device.
Events meeting the AE definition
!Any abnormal laboratory test results or safety assessments, including those that worsen from baseline, 
considered clinically significant in the medical and scientific judgment of the investigator.
!A clinical abnormal laboratory finding which is clinically significant, i.e. an abnormality that suggests a 
disease and/or organ toxicity and is of a severity that requires active management. Active management includes active treatment or further investigations, for example change of medicine dose or more frequent follow-up due to the abnormality.
!Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency 
and/or intensity of the condition.
!Signs, symptoms or the clinical sequelae of a suspected drug-drug interaction.
!Signs, symptoms or the clinical sequelae of a suspected overdose of trial product regardless of intent.
!A "lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or 
SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the definition.
Events NOT meeting the AE definition 
!Pre-existing conditions, anticipated day-to-day flu ctuations of pre-existing conditions, including those 
identified during screening or other trial procedures performed before exposure to trial product. 
Note: pre-existing conditions should be recorded as medical history/concomitant illness.
!Pre-planned procedures, unless the condition for which the procedure was planned has worsened from the first 
trial related activity after the subject has signed the informed consent.
Definition of an SAE
An SAE is an AE that fulfils at least one of the following criteria:
!Results in death
!Is life-threatening
The term 'life-threatening' in the definition of 'serious' refers to an event in which the subject was at risk of death at 
the time of the event. It does not refer to an event which hypothetically might have caused death, if it were more 
severe.
!Requires inpatient hospitalisation or prolongation of existing hospitalisation
Hospitalisation signifies that the subject has been detained at the hospital or emergency ward for observation and/or 
treatment that would not have been appropriate in the physician‚Äôs office or outpatient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event is serious. When in doubt as to whether ‚Äúhospitalisation‚Äù occurred or was necessary, the AE should be considered serious.
Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline is not considered 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 79 of 94
an AE.
Note:
Hospitalisations for administrative, trial related and social purposes do not constitute AEs and should therefore 
not be reported as AEs or SAEs.
Hospital admissions for surgical procedures, planned before trial inclusion, are not considered AEs or SAEs.
!Results in persistent disability/incapacity
The term disability means a substantial disruption of a person‚Äôs ability to conduct normal life functions.
This definition is not intended to include experience of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g. sprained ankle), 
which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
!Is a congenital anomaly/birth defect
!Important medical event:
Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations. 
This includes important medical events that may not be immediately life-threatening or result in death or 
hospitalisation, but may jeopardise the subject or may require medical or surgical intervention to prevent one of the 
other outcomes listed in the above definition. These events should usually be considered serious and reported as SAEs using the important medical event criterion.
The following adverse events must always be reported as SAEs using the important medical event criterion, if no other 
seriousness criteria are applicable:
Suspicion of transmission of infectious agents via the trial product. 
Risk of liver injury defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 x UNL 
and total bilirubin >2 x UNL, where no alternative aetiology exists (Hy's law).
Description of AEs requiring additional data collection (via specific event form) and/or events for adjudication. 
AEs requirin g additional data collection (via specific event form):
Medication error:
A medication error concerning trial products is defined as:
!Administration of wrong drug 
Note: Use of wrong DUN is not considered a medication error unless it results in a confirmed administration of 
wrong drug. 
!Wrong route of administration, such as intramuscular instead of subcutaneous. 
!Accidental administration of a lower or higher dose than intended. Accidental administration of a lower or 
higher dose than intended. i.e. dose which may lead to significant health consequences, as judged by the 
Investigator, irrespective of whether the SAE criteria are fulfilled or not; however, the administered dose must deviate from the intended dose to an extent where clinical consequences for the trial subject were likely to 
happen as judged by the investigator, although they did not necessarily occur.
Events for adjudication
Event type Description Adjudication outcome
Acute coronary syndrome Acute Coronary Syndrome
conditions include all types of 
acute myocardial infarction and hospitalisation for unstable 
angina pectoris!Acute myocardial infarction 
(including subgroup 
classifications)
!Hospitalisation for unstable 
angina pectoris
Cerebrovascular events Episode of focal or global 
neurological dysfunction that could be caused by brain, spinal !Ischaemic stroke
!Haemorrhagic stroke
!Undetermined stroke
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 80 of 94
cord, or retinal vascular injury as 
a result of haemorrhage or infarction
Heart failure Presentation of the subject for an 
urgent, unscheduled 
clinic/office/emergency 
department visit or hospital admission, with a primary 
diagnosis of heart failure (new
episode or worsening of existing 
heart failure)!Heart failure hospitalisation
!Urgent heart failure visit
Death All cause death !Cardiovascular death 
(including undetermined cause of death)
!Non-Cardiovascular death
Hypersensitivity 
!Local reactions, 
including injection site 
reactions  
!Systemic reactions, 
including anaphylaxisHypersensitivity is defined as 
episodes of objectively reproducible symptoms or signs 
initiated by exposure to a 
defined stimulus at a dose 
tolerated by normal persons
Anaphylaxis is defined as 
serious hypersensitivity 
reactions that is rapid in onset 
and may cause death!Hypersensitivity reaction
AE and SAE recording
!The investigator will record all relevant AE/SAE information in the CRF.
!The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other 
clinical information. In such cases, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.
!When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g. hospital 
progress notes, laboratory and diagnostics reports) related to the event.
!For all non-serious AEs the applicable forms should be signed when the event is resolved or at the end of the 
trial at the latest. For sign-off of SAE related forms refer to ‚ÄúSAE reporting via paper CRF‚Äù later in this 
section.
!Novo Nordisk products used as concomitant medication if an AE is considered to have a causal relationship 
with a Novo Nordisk marketed product used as concomitant medication in the trial, it is important that the 
suspected relationship is reported to Novo Nordisk, e.g. in the alternative aetiology section on the safety information form. Novo Nordisk may need to report this adverse event to relevant regulatory authorities.
Assessment of severity
The investigator will assess intensity for each event reported during the trial and assign it to one of the following 
categories: 
!Mild : An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with 
everyday activities.
!Moderate : An event that causes sufficient discomfort and interferes with normal everyday activities.
!Severe : An event that prevents normal everyday activities. 
Note: Severe is a category used for rating the intensity of an event; and both an AE and SAE can be assessed as severe. An event is defined as ‚Äòserious‚Äô when it meets at least one of the outcomes described in the definition of an 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 81 of 94
SAE and not when it is rated as severe.
Assessment of causality
The investigator is obligated to assess the relationship between trial product and the occurrence of each AE/SAE.
Relationship between an AE/SAE and the relevant trial product(s) should be assessed as: 
!Probable - Good reason and sufficient documentation to assume a causal relationship.
!Possible - A causal relationship is conceivable and cannot be dismissed.
!Unlikely - The event is most likely related to aetiology other than the trial product.
Alternative aetiology, such as underlying disease(s), concomitant medication, and other risk factors, as well as the 
temporal relationship of the event to trial product administration will be considered and investigated.
The investigator should use the investigator‚Äôs brochure for insulin 287 and/or product information for marketed non-
Novo Nordisk's products, for the assessment. For each AE/SAE, the investigator must document in the medical records 
that he/she has reviewed the AE/SAE and has provided an assessment of causality.
There may be situations in which an SAE has occurred and the investigator has minimal information to include in the 
initial report. However, it is important that the investigator always makes an assessment of causality for every 
event before the initial transmission of the SAE data .
The investigator may change his/her opinion of causality in light of follow-up information and send a follow-up report 
with the updated causality assessment.
The causality assessment is one of the criteria used when determining regulatory reporting requirements.
Final outcome
The investigator will select the most appropriate outcome:
!Recovered/resolved: The subject has fully recovered, or by medical or surgical treatment the condition has 
returned to the level observed at the first trial-related activity after the subject signed the informed consent.
!Recovering/resolving: The condition is improving and the subject is expected to recover from the event. This 
term is only applicable if the subject has completed the trial or has died from another AE.
!Recovered/resolved with sequelae: The subject has recovered from the condition, but with lasting effect due 
to a disease, injury, treatment or procedure. If a sequelae meets an SAE criterion, the AE must be reported as 
an SAE.
!Not recovered/not resolved: The condition of the subject has not improved and the symptoms are unchanged 
or the outcome is not known.
!Fatal: This term is only applicable if the subject died from a condition related to the reported AE. Outcomes of 
other reported AEs in a subject before he/she died should be assessed as ‚Äúrecovered/resolved‚Äù, 
‚Äúrecovering/resolving‚Äù, ‚Äúrecovered/resolved with sequelae‚Äù or ‚Äúnot recovered/not resolved‚Äù. An AE with a 
fatal outcome must be reported as an SAE.
!Unknown: This term is only applicable if the subject is lost to follow-up.
Follow-up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as 
medically indicated or as requested by Novo Nordisk to elucidate the nature and/or causality of the AE or SAE as fully as possible (e.g. severe hypersensitivity reactions). This may include additional laboratory tests (e.g. skin prick test) or 
investigations, histopathological examinations, or consultation with other health care professionals.
New or updated information will be recorded in the CRF.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 82 of 94
SAEs : All SAEs must be followed until the outcome of the event is ‚Äúrecovered/resolved‚Äù, ‚Äúrecovered/resolved with 
sequelae‚Äù or ‚Äúfatal‚Äù, and until all queries have been resolved. Cases of chronic conditions, cancer or AEs ongoing at 
time of death (where death is due to another AE) may be closed with the outcome ‚Äúrecovering/resolving‚Äù or ‚Äúnot recovered/not resolved‚Äù. Cases can be closed with the outcome of ‚Äúrecovering/resolving‚Äù when the subject has 
completed the follow-up period and is expected by the investigator to recover.
The SAE follow-up information should only include new (e.g. corrections or additional) information and must be 
reported within 24 hours of the investigator‚Äôs first knowledge of the information. This is also the case for previously 
non-serious AEs which subsequently become SAEs.
Non-serious AEs : Non-serious AEs must be followed until the outcome of the event is ‚Äúrecovering/resolving‚Äù, 
‚Äúrecovered/resolved‚Äù or ‚Äúrecovered/resolved with sequelae‚Äù or until the end of the follow-up period stated in the protocol, whichever comes first, and until all queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) may be closed with the outcome 
‚Äúrecovering/resolving‚Äù or ‚Äúnot recovered/not resolved‚Äù. Cases can be closed with the outcome of ‚Äúrecovering/resolving‚Äù when the subject has completed the follow-up period and is expected by the investigator to 
recover.
The investigator must ensure that the recording of the worst case severity and seriousness of an event is kept throughout 
the trial. A worsening of an unresolved AE must be reported as follow up with re-assessment of severity and/or 
seriousness of the event.
SAE reporting via electronic CRF
!Relevant forms (AE and safety information form) must be completed in the CRF. 
!For reporting and sign-off timelines, see box below. 
!If the CRF is unavailable for more than 24 hours, then the site will use the paper AE form and if the CRF is 
unavailable for more than 5 calendar days then the site will use the safety information form (see box below).
!The site will enter the SAE data into the CRF as soon as it becomes available, see 9.2.1.
!After the trial is completed at a given site, the CRF will be decommissioned to prevent the entry of new data or 
changes to existing data. If a site receives a report of a new SAE from a subject or receives updated data on a 
previously reported SAE after CRF decommission, then the site can report this information on a paper AE and safety information form (see box below) or to Novo Nordisk by telephone.
SAE reporting via paper CRF
!Relevant CRF forms (AE and safety information form) must be forwarded to Novo Nordisk either by fax, e-mail or 
courier.
!Initial notification via telephone is acceptable, although it does not replace the need for the investigator to complete 
the AE and safety information form within the designated reporting time frames (as illustrated in Figure 9-1 ):
!AE form within 24 hours.
!Safety information form w ithin 5 calendar days. 
!Both forms must be signed within 7 calendar days.
Contact details for SAE reporting can be found in the investigator trial master file.
Reporting of AEs for Non-Novo Nordisk medical devices provided by Novo Nordisk for use in the trial
Reporting of AEs on:  FreeStyle Libre Pro device and supplies or BG meter device and related auxiliaries 
All technical complaints on  FreeStyle Libre Pro and supplies or BG-meter, strips, lancets and control solutions 
must be reported directly to the supplier/manufacturer using the supplier reporting form within the timelines defined 
from supplier/manufacturer.
Contact details are provided in Attachment I to the protocol
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 83 of 94
Contraceptive guidance and collection of pregnancy Appendix 5
information
It must be recorded in the CRF whether female subjects are of childbearing potential. 
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile. 
Women in the following categories are not considered WOCBP
1. Premenarcheal 2. Premenopausal female with one of the following:
!Documented hysterectomy
!Documented bilateral salpingectomy
!Documented bilateral oophorectomy
Note: Documentation can come from the site personnel‚Äôs review of subject‚Äôs medical records, 
medical examination or medical history interview.
3. Postmenopausal female
!A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high Follicle Stimulating Hormone  (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using hormonal 
contraception or Hormonal Replacement Therapy (HRT). However, in the absence of 12 
months of amenorrhea, a single FSH measurement is insufficient. 
!Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non-hormonal highl y effective contraception methods if they wish to continue their 
HRT during the trial. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before trial enrolment.
Contraception guidance
Male subjects 
No contraception measures are required for male subjects as the risk of teratogenicity/fetotoxicity caused by transfer of insulin 287 or insulin  glargine in seminal  fluid is unlikely.
Female subjects
Female subjects of childbearing potential are eligible to participate if they agree to use methods of contraception consistently and correctly as described in table(s) below:
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 84 of 94
Table 12-3 Highly effective contraceptive methods
Highly effective contraceptive methods that are user dependenta 
Failure rate of <1% per year when used consistently and correctly.
Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation b
!oral 
!intravaginal 
!transdermal 
Progestogen only hormonal contraception associated with inhibition of ovulation
!oral 
!injectable 
Highly effective methods that are user independenta 
Implantable progestogen only hormonal contraception associated with inhibition of ovulation 
!Intrauterine Device (IUD)
!Intrauterine hormone-releasing System (IUS)
!Bilateral tubal occlusion
Vasectomised partner 
A vasectomised partner is a highly effective contraception method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used.
Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the trial product. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the subject.
Notes: 
aFailure rates may differ from < 1% per year, if not used consistently and correctly. Use should be consistent with local 
regulations regarding the use of contraceptive methods for subjects participating in clinical trials. 
Pregnancy testing
!WOCBP should only be included after a negative highly sensitive serum pregnancy test.
!Urine Pregnancy testing should be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected.
Collection of pregnancy information
Female subjects who become pregnant 
!Investigator will collect pregnancy information on any female subject, who becomes 
pregnant while participating in this trial.
!Information will be reco rded on the appropriate form and submitted to Novo Nordisk within 
14 calendar days of learning of a subject's pregnancy.
!Subject will be followed to determine the outcome of the pregnancy. The investigator will 
collect follow-up information on subject and neonate, which will be forwarded to Novo 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 85 of 94
Nordisk. Generally, fo llow-up will not be required for longer than 1 month beyond the 
delivery date.
!Any termination of pregnancy will be repor ted, regardless of foetal status (presence or 
absence of anomalies) or indication for procedure.
!While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication 
or elective termination of a pregnancy will be reported as an AE or SAE. 
!A spontaneous abortion is always considered to be an SAE and will be reported as such.
!Any SAE occurring as a result of a post-trial pregnancy which is considered 
possibly/probably related to th e trial product by the investig ator will be reported to Novo 
Nordisk as described in Appendix 4 . While the investigator is not obligated to actively seek 
this information in former subjects, he or she may learn of an SAE through spontaneous 
reporting. 
Any female subject who becomes pregnant while participating in the trial will discontinue trial 
product. 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 86 of 94
Technical complaints: Definition and procedures for Appendix 6
recording, evaluation, follow-up and reporting 
Technical complaint definition 
!A technical complaint is any written, electronic or oral communication that alleges product (medicine or 
device) defects. The technical complaint may be associated with an AE, but does not concern the AE itself.
Examples of technical complaints:
!Problems with the physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination).
!Problems with packaging material including labelling.
!Problems related to medical devices (e.g. to the injection mechanism, dose setting mechanism, push button or 
interface between the pen-injector and the needle).
Time period for detecting technical complaints 
All technical complaints, which occur from the time of receipt of the product at trial site until the time of the last usage 
of the product, must be collected for products predefined on the technical complaint form. 
Reporting of technical complaints to Novo Nordisk
Contact details (fax, e-mail and address) for Customer Complaint Center ‚Äì refer to Attachment I
Technical complaints must be reported on a separate technical complaint form:
1. One technical complaint form must be completed for each affected DUN
2. If DUN is not available, a technical complaint form for each batch, code or lot number must be completed
Timelines for reporting of technical complaints to Novo Nordisk
The investigator must complete the technical complaint form in the CRF within the timelines specified in Figure 9-3 . If 
the CRF is unavailable or when reporting a technical complaint that is not subject related, the information must be 
provided on a paper form by fax, e-mail or courier to Customer Complaint Center, Novo Nordisk, within the same 
timelines as stated above. When the CRF becomes available again, the investigator must enter the information on the 
technical complaint form in the CRF.
Follow-up of technical complaints 
The investigator is responsible for ensuring that new or updated information will be recorded on the originally 
completed form . 
Collection, storage and shipment of technical complaint samples
The investigator must collect the technical complaint sample and all associated parts that were packed in the same DUN 
and notify the monitor within 5 calendar days of obtaining the sample at trial site. The sample and all associated parts must be sent as soon as possible to Customer Complaint Center, Novo Nordisk, together with a copy of the completed technical complaint form. The technical complaint sample should contain the batch, code or lot number and, if 
available, the DUN. If the technical complaint sample is unobtainable, the reason must be stated on the technical 
complaint form. If several samples are shipped in one shipment, the sample and the corresponding technical complaint 
form should be kept together.
Storage of the technical complaint sample must be done in accordance with the conditions prescribed for the product.
Reporting of technical complaints for Novo Nordisk products not included in technical complaint form
Technical complaints on Novo Nordisk products not included in the technical complaint form should be reported to 
local Novo Nordisk affiliate with a reference to trial ID.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 87 of 94
Retention of human biosamples Appendix 7
Anti-insulin 287 antibodies, anti-insulin glargine antibodies samples and samples to assess systemic 
hypersensitivity reactions (if taken) will be stored at a central bio-repository after end of trial and 
until marketing authorisation approval or until the research project terminates, but no longer than 15 
years from end of trial after which they will be destroyed.
Antibody samples may be used for later analysis for further characterisation of antibody responses 
towards drug, if required by health authorities or for safety reasons, or for exploratory investigation 
of antibodies or further development of anti-insulin antibody assays.
The subject‚Äôs identity will remain confidential and the antibo dy samples will be identified only by 
subject number, visit number and trial identification num ber. No direct identi fication of the subject 
will be stored together with the samples.
Only Novo Nordisk staff and biorepository personnel will have access to the stored samples.
Subjects can contact the investigator if they wish to be informed about results derived from stored 
biosamples obtained from their own body.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 88 of 94
Hypoglycaemic episodes Appendix 8
Classification of hypoglycaemia
Classification of hypoglycaemia
Level Glycaemic criteria Description
Hypoglycaemia alert 
value ( level 1 )< 3.9 mmol/L (70 mg/dL) 
and 
‚â• 3.0 mmol/L (54 mg/dL)  Sufficiently low for tr eatment with fast -
acting carbohydrate and dose 
adjustment of glucose-lowering therapy
Clinically significanthypoglycaemia ( level 
2)< 3.0 mmol/L (54 mg/dL) Sufficiently low to indicate serious, 
clinically important hypoglycaemia
Severe hypoglycaemia 
(level 3 )No specific glucose 
thresholdHypoglycaemia associated with severe 
cognitive impairment requiring
external assistance for recovery
Notes: Novo Nordisk terms adapted from IHSG30, ADA-2018 4, ISPAD31, Type 1 diabetes 
outcomes program32, ATTD33. Severe hypoglycaemia as defined by Seaquist34.
Reporting of hypoglycaemic episodes:
Plasma Glucose (PG) should always be measured by  the study provided BG meter and r ecorded in 
the diary and CRF when a hypoglycaemic episode is suspected. 
PG values <3.9 mmol/L (70 mg/dL) should be re ported as a hypoglycaemic episode according to 
the instructions below. When a subject experiences a hypoglycaemic episode, subject/investigator should record the general information in relation to the hypoglycae mia (timing, PG measurements, symptoms etc.) as described in the diary/CRF, respectively. In case a subject is not able to fill in the 
diary (e.g. in case of hospitalisation), the invest igator should report the hypoglycaemic episode in 
the hypoglycaemic episode CRF.
Upon onset of a hypoglycaemic episode the subject is recommended to measure PG  every 15 
minutes until the SMPG value is ‚â•3.9 mmol/L (70 mg/dL) and in case of severe hypoglycaemia, 
that the condition have been resolved in accordance with current guidelines
34.Furthermore, subjects 
should be encouraged to measure and follow their SMPG values 1-2 hours after the episode.
Repeated SMPG measurements and/or symptoms will by default be considered as one 
hypoglycaemic episode until a succeeding SMPG value is ‚â• 3.9 mmol/L (70 mg/dL) and/or 
symptoms have been resolved. The episode should be reported as only one hypoglycaemic episode on the hypoglycaemic episode CRF. In case of several low SMPG values within the hypoglycaemic episode, the lowest value is the one that will be reported as the SMPG value for the hypoglycaemic 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 89 of 94
episode but the start time of the episode will remain as the time for the first low SMPG value and/or 
symptom. The remaining values will be kept as source data in the diary. 
If the severity of a hypoglycaemic episode changes, only one hypoglycaemic episode should be 
reported, reflecting the most severe degree of hypoglycaemia.
Regarding the question: ‚ÄúTo feel better, did y ou need help to get a sugary drink, food, or 
medicine?‚Äù the investigator must instruct subjects th at the answer should be ‚ÄúYes‚Äù, if the episode is 
an event requiring assistance of another pers on to actively administer carbohydrate, glucagon, or 
take other corrective actions. PG concentrations may not be available during an event, but 
neurological recovery fo llowing the return of PG to normal is considered sufficient evidence that the event was induced by a low PG concentration.
34
Additional information (e.g. description of symptoms, alleviation of symptoms, seizure or coma) in relation to severe hypoglycaemic episodes must be recorded in the hypoglycaemic episode CRF.
Diary Review
At each visit or phone contact, the investigator must review the diary for low SMPG values not 
reported as hypoglycaemic episodes. The subject must be questioned whether any of the low values were severe, i.e. whether the subject could have handled the episode (by getting a sugary drink and/or food) him/herself. If the subject could not have handled the episode him/herself, it has to be 
reported as a hypoglycaemic episode in the hypoglycaemic episode CRF describing that the subject 
could not have handled the episode him/herself. 
For low SMPG values for hypoglycaemic episodes where the subject could handle the episode 
him/herself: 
!If a hypoglycaemic episode form in the diary is not completed by the subject within 7 
calendar days of the SMPG measurement, the ep isode should be described in the source 
documents and reported by the investigato r on a hypoglycaemic episode CRF with as much 
information as possible: Novo Nordisk will not query for additional data except for the start date and whether the subject could have handled the episode him/herself due to the 
decreased validity of such data.
35 36
Re-training of subjects
The subject must be re-trained in how to report hypoglycaemic episodes if the investigator identifies 
low SMPG values not reported as hypoglycaemic episodes. The training should be documented by 
the investigator in source documents.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 90 of 94
Titration guideline Appendix 9
Introduction
Titration guidelines have been developed, providing recommended dose adjustments at different PG 
levels to ensure that subjects receive an optimal treatment. However, it is recognised that insulin 
treatment should be individualised and the specif ic titration algorithms may not be applicable in 
certain clinical situations. Hence, it is important that other information, such as symptoms of hypo/hyperglycaemia, previous response to dose adjustments, other glucose measurements and other indicators of the subject‚Äôs level of glycaemic control, is taken into consideration when 
decisions on dosing are made. The investigator is responsible for the treatment of the subjects and 
can therefore overrule the guidelines to avoid safety hazards.
Initiation of trial products
At randomisation eligible subjects will be randomised to receive insulin 287 + insulin glargine-
placebo or insulin 287-placebo + insulin glargine.
Insulin 287 and insulin 287-placebo should be taken once weekly at the same day of the week. The 
starting dose will be 70U.
Insulin glargine and insulin glargine-placebo will be  taken once daily anytime of the day preferably 
the same time every day. The starting dose will be 10U.
The treat-to-target approach will be applied in both treatments to optimise titration and glycaemic 
control throughout the trial.
There are no maximum or minimum doses.
Dose adjustment of trial products during the trial
Titration of insulin glargine and insulin glargine-placebo
After randomisation insulin glargine and insulin glargine-placebo doses will be adjusted once 
weekly by the investigator in connection with the scheduled visits/phon e contacts as described 
below. Titrated dosed should be maintained until new titration or review is performed by the 
Investigator.
The dose adjustment will be based on the three pre-breakfast SMPG values measured on two days 
prior to titration and on the day of the contact.
If one or more SMPG values are missing, the dose adjustment should be performed on the 
remaining SMPG value(s). The insulin dose adjustment should aim to reach an SMPG of 3.9‚Äì6.0 mmol/L (70 ‚Äì108 mg/dL).
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 91 of 94
If there are no hypoglycaemic values in the pre-breakfast SMPGs value(s) the dose is adjusted 
according to Table 12-4 . If there are hypoglycaemic values the dose is adjusted according to 
Table 12-5
Table 12-4 Insulin glargine and insulin glargine-placebo increase
Mean pre-breakfast SMPG Dose adjustment
mmol/L mg/dL U
3.9 ‚Äì 6.0 70 ‚Äì 108 No adjustment
6.1 ‚Äì 7.0 109 ‚Äì 126 + 2
> 7.0 > 126 + 4
Table 12-5 Insulin glargine and insulin glargine-placebo reduction
Lowest pre-breakfast SMPG Dose adjustment
mmol/L mg/dL U
3.0 ‚Äì 3.8 54 ‚Äì 69 - 2
< 3.0 < 54 - 4
Titration of insulin 287 and insulin 287-placebo
The dose adjustment will be based on the three fasting SMPG values measured on two days prior to 
titration and on the day of the contact.
If one or more SMPG values are missing, the dose adjustment should be performed on the 
remaining SMPG value(s). The insulin dose adjustment should aim to reach a SMPG of 3.9‚Äì6.0
mmol/L (70 ‚Äì108 mg/dL).
If there are no hypoglycaemic values in the fasting SMPGs value(s) the dose is adjusted according 
to Table 12-6 . If there are hypoglycaemic values the dose is adjusted according to Table 12-7
Table 12-6 Insulin 287 and insulin 287-placebo increase
Mean pre-breakfast SMPG Dose adjustment
mmol/L mg/dL U
3.9 ‚Äì 6.0 70 ‚Äì 108 No adjustment
6.1 ‚Äì 7.0 109 ‚Äì 126 + 14
> 7.0 > 126 + 28
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 92 of 94
Table 12-7 Insulin 287 and insulin 287-placebo reduction
Lowest pre-breakfast SMPG Dose adjustment
mmol/L mg/dL U
3.0 ‚Äì 3.8 54 ‚Äì 69 - 14
< 3.0 < 54 - 28
Deviations from the algorithm
It is recommended that the algorithm is followe d. The prescribed daily dose must always 
correspond to the prescribed weekly dose divided by 7. However, it is also important that the 
decision to adjust insulin doses is based on all relevant information. A reason for deviating from the 
algorithm should be entered into the eCRF by the investigator as app licable.
Missing dose guidance: 
The dosing window is ¬±1 day. If a dose is missed for ‚â§ 4 days after the planned dosing day, subjects 
should inject the planned full dose as soon as possible and perform control SMPG measurement. If 
the missing dose is observed from da y 5 to day 7 (which is the ne xt p lanned dosing day), subject 
should inject 50% of the missed dose rounded down to the closest possible dose which can be divided with 7. If a subject forgot to take the prescribed dose of 77U, then 50% of 77U is 38.5U and hence the dose should be rounded down to 35U. On day 7, the next scheduled dosing should st ill be 
taken. Additional SMPG measurement should be performed to control BG.
Dose recommendation from V28 (end of treatment) and during follow up
If it is decided that the individual subject should continue on insulin from V28 it is recommended 
that the subject is switched to any available basal insulin at the discretion of the investigator. The 
initial post-trial basal dose is estimated as follows:
!Calculate 50% of the latest daily insulin glargine/insulin glargine-placebo dose
!Calculate 50% of the latest weekly insulin 287/insulin 287-placebo dose divided by 7
!Initiate the new daily basal insulin based on the lowest of the two calculated doses above
!Consider titrating the basal insulin once or twice weekly in accordance with Table 12-4 and 
Table 12-5 during the follow up period
Data collection
The following data should be entered into the diary by the subject and reviewed by the investigator 
prior to the contact:
!Per protocol pre-breakfast SMPG values measured since last visit/telephone contact
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
Status: Final
Page: 93 of 94
!Insulin glargine/insulin glargine-placebo and insulin 287/insulin 287-placebo doses taken 
prior to the visit/phone contact
The following should be entered by investigator in to the eCRF within 24 hours afte r each contact:
!Insulin glargine/insulin glargine-placebo and insulin 287/insulin 287-placebo doses 
prescribed at this contact.
!Reasons for deviation from the titration algorithms, if applicable
!Hypoglycaemic episodes
Data surveillance
Surveillance of titration data will be performed centrally  by Novo Nordisk in an unbiased or, if 
possible, a blinded manner. The data will be reviewed and significant changes from the titration 
algorithm will be followed up. 
It is important that data regarding dose titration is en tered into the diary and into the eCRF. If delays 
occur, action cannot be taken in due time before the subject‚Äôs next site visit/phone contact. The aim is to reduce the time periods in which a subject may receive suboptimal treatment.
The titration data should be reviewed by Novo Nordisk within 24 hours (on workdays). The 
reviewer may contact the investigator by e-mail or phone to clarify reasons for deviation or to 
request entry of missing data. When the investigator receives an inquiry, a response should be received at Novo Nordisk within 24 hours (on workdays).
In addition, Novo Nordisk w ill monitor changes in HbA
1c. Novo Nordisk may visit or phone sites to 
discuss progress in glycaemic control and titration of individual subjects.
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 25 June 2018 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
     Status: Final
     Page: 94 of 94
Country-specific requirements Appendix 10
For Czech Republic: Adequate contraceptive measures are always one highly reliable method 
(such as intrauterine device, sterilisation of one of the partners, hormonal birth control methods) plus one supplementary barrier method (such as condom, diaphragm) with a spermicide. In justified 
cases, this combination may be replaced with  a double-barrier method with a spermicide. Total 
sexual abstinence may also be considered contraception. (Please note: Hormonal contraception should always be discussed with a gynaecologist).
For Greece: Adequate contraceptive measures are defined as combined hormonal contraception 
(containing oestrogen and progesterone), which suppress ovulation (oral, intravaginal, 
percutaneous), progesterone-only hormonal contraception which suppress ovulation (oral, 
injectable, implantable), intrauterine device, hormone-releasing intrauterine system, bilateral tubal occlusion, partner with vasectomy, sexual abstinence.
For Poland: Novo Nordisk carries liability for the trial exclusively in the scope defined by the 
applicable laws and in particular by the Civil Code and the Pharmaceut ical Law dated 6 September 
2001 (uniform version Journal of Laws of 2008 No.45 item 271 with amendments). In order to 
support potential claims for liability attributable to the Trial, Novo Nordisk and investigator are covered by Insurance Policy issued according to applicable Polish law.
For Slovakia: It is necessary that the trial sponsor c overs all costs for treatment of the disease 
studied. It is necessary to cover the whole diabetes medication payment, including metformin and DPP4i.
 CONFIDENTIAL
Log of Protocols
INTERNAL USE ONLYDate: 08 January 2020 Novo Nordisk
Trial ID: NN1436-4383 Version: 1.0
     Status: Final
     Page: 1 of 1
Log of 4383 protocols
Please note that text in italics is only here to provide a full overview.
Date Versions Submitted Comments
25-Jun-2018 1.0 Yes First version on the CTA
nD object ID: 
 CONFIDENTIAL
Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staff&21),'(17,$/'DWH Novo Nordisk
9HUVLRQ
6WDWXV11&
7ULDO,'11&OLQLFDO7ULDO5HSRUW
$SSHQGL[0D\

)LQDO
 CONFIDENTIAL